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INTRODUCTION
Foot and ankle pain is common, with an estimated point prev-
alence of 20% (1). For adults aged older than 55, the foot/ankle 
is the third most common site of self- reported joint pain, following 
the knee and the hand/wrist (2). In a rheumatology setting, 64% to 
93% of patients with inflammatory arthritis self- report experienc-
ing foot pain that is moderate to severe (3–5), and patients with 
rheumatoid arthritis whose debut joint is a foot/ankle joint expe-
rience higher disease activity, higher disability, and lower quality 
of life (6). Given the common presentation and significant impact 
of musculoskeletal symptoms involving the foot and ankle, valid 
and reliable patient- reported outcome measures can improve 
assessment and management. The aim of this review was to pro-
vide an overview of the most common outcome measures used 
to evaluate foot pain, foot function, and general foot health for 
adults with musculoskeletal symptoms of the foot and ankle. Spe-
cific objectives were to demonstrate the practical application of 
each outcome measure, to describe the psychometrics of each 
instrument, and to provide a critical appraisal of each instrument 
to the rheumatology community.
To identify outcome measures for inclusion, we used a 
recently published systematic review of patient- reported out-
come measures for foot and ankle conditions (7). Outcome meas-
ures were eligible if they evaluated the foot or foot and ankle (but 
not the ankle only); evaluated pain, function, or general foot health; 
and evaluated musculoskeletal symptoms. Outcome measures 
were excluded if they evaluated specific conditions (eg, Achilles 
tendinopathy) or were generic pain or function measures (eg, 
visual analog scale [VAS] or 36- Item Short Form Health Survey 
[SF- 36]). Eligible outcome measures were ranked based on how 
frequently they have been used over the past 10 years. To deter-
mine the rank, we searched the title of the outcome measure in 
PubMed and Google Scholar and used the number of times the 
original article describing the outcome measure had been cited. 
This information is provided in the Supplementary Material.
The 10 most frequently used outcome measures over the 
past 10 years are the American Orthopaedic Foot and Ankle 
Society (AOFAS) Clinical Rating Scales, the Foot and Ankle Abil-
ity Measure (FAAM), the Foot and Ankle Outcome Score (FAOS), 
the Foot Function Index–Revised (FFI- R), the Foot Health Status 
Questionnaire (FHSQ), the Leeds Foot Impact Scale for Rheu-
matoid Arthritis (LFIS- RA), the Manchester Foot Pain and Disa-
bility Index (MFPDI), the Manchester- Oxford Foot Questionnaire 
(MOXFQ), the Self- Reported Foot and Ankle Score (SEFAS), and 
the Visual Analog Scale–Foot and Ankle (VAS- FA).
AMERICAN ORTHOPAEDIC FOOT AND ANKLE 
SOCIETY CLINICAL RATING SCALES: ANKLE/
HINDFOOT (AOFAS- AH), MIDFOOT (AOFAS- M), 
HALLUX (AOFAS- HJ), AND LESSER (AOFAS- LJ)
Description
Purpose. To provide a standardized method of reporting the 
clinical status of the foot and ankle (8).
Content or domains. The AOFAS Clinical Rating Scales are 
four separate outcome measures that evaluate different anatomic 
regions of the foot and ankle: the ankle/hindfoot (AOFAS- AH), 
the midfoot (AOFAS- M), the hallux metatarsophalangeal- 
interphalangeal (AOFAS- HJ), and the lesser metatarsophalangeal- 
interphalangeal (AOFAS- LJ). Each outcome measure evaluates 
pain (one item), function (five to seven items) and alignment 
(one item).
Number of items. AOFAS- AH: nine items; AOFAS- M: 
seven items; AOFAS- HJ: eight items; and AOFAS- LJ: eight items.
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Response options/scale. A combination of subjective 
patient- reported items that are scored by using 3- or 4- point Lik-
ert scales and clinician- led objective measures that are scored by 
using 2- to 3- point Likert scales.
Recall period for items. Unspecified.
Cost to use. Free.
How to obtain. Each outcome measure is described in the 
original article (8). An online calculator is also available at www.
ortho toolk it.com.
Practical application
Method of administration. Patient and clinician adminis-
tered with paper and pencil.
Scoring. Each item is scored from 0 (representing the worst 
foot status) to scores that range from 5 to 40, depending on the 
item (representing the best foot status). The items are summed to 
give a total score of 100.
Score interpretation. Total scores range from 0 (repre-
senting the worst foot status) to 100 (representing the best foot 
status). Normative data from a sample of 625 people who were 
visitors or employees of a hospital in Germany have been pub-
lished (9).
Respondent time to complete. Five minutes.
Administrative burden. Calculation of the total score 
takes less than 1 minute per participant. The clinician is required 
to perform a joint range of motion assessment and observational 
gait analysis.
Translations/adaptations. The AOFAS- AH has been 
translated and culturally adapted into Dutch (10), German (11), 
Italian (12), Persian (13,14), Portuguese (15), and Turkish (16).
Psychometric information
Floor and ceiling effects. No floor or ceiling effects were 
observed for the AOFAS- AH in people with an acute ankle sprain 
(17) or for people with any foot or ankle condition (13,18,19). A 
ceiling effect was observed for the AOFAS- M in people with Lis-
franc joint injury (20). No floor or ceiling effects were observed for 
the AOFAS- HJ in people with any foot or ankle condition (19). 
Ceiling effects were observed for the AOFAS- LJ in people with 
rheumatoid arthritis and people with no foot or ankle complaints 
(21).
Reliability. The AOFAS published a position statement in 
2011 that outlined the AOFAS Clinical Rating Scales as not reliable 
(22). However, a recent article found moderate internal consist-
ency (Cronbach’s α = 0.75) for the AOFAS- M for 117 people with 
Lisfranc joint injury (20).
Validity. The AOFAS published a position statement in 2011 
that outlined the AOFAS Clinical Rating Scales as not valid (22).
Responsiveness. Responsiveness of the AOFAS Clinical 
Rating Scales (assessed by combining scores from each version 
and reported by using the standardized response mean [SRM] 
and effect sizes) was evaluated in a relatively small sample of 25 
people with a foot or ankle condition that required surgical inter-
vention. An SRM of 1.10 and an effect size of 1.12 suggest an 
acceptable responsiveness to change (23). Acceptable respon-
siveness to change was reported for the AOFAS- AH in a larger 
sample of 117 patients who underwent surgery for ankle arthritis 
(SRM 1.34; effect size 1.69) (24) and for 91 people with hallux val-
gus (area under the receiver operating characteristic [ROC] curve 
of all scales ranged between 0.80 and 0.87) (25).
Minimally important differences. Minimally important 
differences have been determined from a sample of 446 patients 
who underwent hallux valgus surgery. These scores ranged from 
7.9 to 30.2, depending on the method of calculation (26).
Generalizability. The AOFAS Clinical Rating Scales are 
the most frequently used outcome measures in orthopedic set-
tings (27,28). However, it is difficult to determine whether this 
questionnaire is generalizable to other populations because the 
scales are not reliable or valid (22).
Use in clinical trials. The AOFAS Clinical Rating Scales 
are among the most frequently used outcome measures in foot 
and ankle research (29), despite recommendations against their 
use. The questionnaires have been used as outcome measures 
of clinical trials evaluating rheumatoid arthritis (30), ankle arthritis 
(31), ankle sprain (32), tibial fracture (33), ankle fracture (34), cal-
caneal fracture (35), Lisfranc injury (36), metatarsal fracture (37), 
Achilles tendinopathy (38), plantar fasciitis (39), and hallux valgus 
(40–43).
Critical appraisal of overall value to the  
rheumatology community
Strengths. The AOFAS Clinical Rating Scales are individ-
ualized to different anatomical regions of the foot and ankle. The 
AOFAS- AH is responsive for certain conditions. The AOFAS Clin-
ical Rating Scales are easy to administer and score and can be 
performed quickly in a clinical setting.
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Caveats and cautions. The AOFAS Clinical Rating Scales 
are not reliable or valid, and the use of these scales is discouraged 
by the AOFAS (22).
Clinical usability. The use of the AOFAS Clinical Rating 
Scales in clinical practice should be discouraged, despite the ease 
of use of these questionnaires.
Research usability. The use of the AOFAS Clinical Rating 
Scales in a research setting should be discouraged because of 
the lack of reliability and validity (22). Furthermore, it has been sug-
gested that these scales produce a skewed distribution, and the 
interpretation of research findings based on the AOFAS Clinical 
Rating Scales should be regarded with caution (44).
FOOT AND ANKLE ABILITY MEASURE
Description
Purpose. To evaluate changes in self- reported physical 
function for individuals with leg, ankle, and foot musculoskeletal 
conditions (45).
Content or domains. The FAAM evaluates two domains: 
activities of daily living (21 items) and sports (6 items).
Number of items. Twenty- nine items.
Response options/scale. Five- point Likert scales.
Recall period for items. One week.
Cost to use. Free.
How to obtain. The formatted questionnaire can be down-
loaded from https://www.aaos.org/quality/research-resources/
patient-reported-outcome-measures/lower-extremity-perfor 
mance-measures/. An online calculator is also available at www.
ortho toolk it.com/faam.
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. Each item is scored from 0 (“unable to do”) to 4 
(“no difficulty”). An “N/A” option is available for each item, and if 
this option is selected, the item is excluded from the total score. 
The activities of daily living subscale and the sports subscale are 
scored separately. The total score is calculated by dividing the 
summed score by the maximum possible score (ie, for the activ-
ities of daily living subscale, if all items are answered, a summed 
score of 60 would be divided by 84. If one item was marked “N/A,” 
the summed score of 60 would be divided by 80). This figure is 
then multiplied by 100 and reported as a percentage (45).
Score interpretation. Subscale scores range from 0 (rep-
resenting the worst physical function) to 100 (representing the best 
physical function). Normative data from a sample of 271 people 
from the general population in the United States have been pub-
lished in a conference abstract (46). The average FAAM activities 
of daily living subscale score was 92.3 (SD 12.3), and the average 
FAAM sports subscale score was 85.1 (SD 20.2).
Respondent time to complete. Five to 10 minutes.
Administrative burden. Self- study of the scoring docu-
mentation (45).
Translations/adaptations. The FAAM has been trans-
lated and culturally adapted into Brazilian Portuguese (47), Chi-
nese (48), German (49), Italian (50), Japanese (51), Spanish (52), 
and Turkish (53). Translation without cultural adaptation has been 
performed for Dutch (54), French (55), Persian (56), and Thai (57).
Psychometric information
Floor and ceiling effects. No floor or ceiling effects were found 
in the original study, which has also been reported for translations of 
the FAAM in Turkish, Dutch, and Persian (45,53,54,56). One study that 
evaluated the responsiveness of the FAAM in a sample of participants 
with diabetes found a floor effect for the sports subscale (58).
Reliability. For the activities of daily living subscale, internal 
consistency (Cronbach’s α) in the original study of 164 patients with 
a new leg, ankle, or foot musculoskeletal condition was 0.98, and 
for 79 patients with an existing leg, ankle, or foot musculoskeletal 
condition, it was 0.96. For the sports subscale, Cronbach’s α was 
calculated for new and existing patients combined and was 0.98 
(45). Similar internal consistency (by using the Rasch measure-
ment model) was observed for the activities of daily living subscale 
(0.87) and the sports subscale (0.89) in a study of 456 patients who 
underwent surgery for an ankle injury (59). Test- retest reliability (intr-
aclass correlation coefficients) for 79 patients with an existing leg, 
ankle, or foot musculoskeletal condition was 0.89 for the activities 
of daily living subscale and 0.87 for the sports subscale (45).
Validity. Content validity was demonstrated in the original 
publication by using item response theory and an evaluation of 
individual items by expert clinicians. Criterion validity has not been 
evaluated because of the absence of a gold standard measure of 
foot function. Construct validity has been demonstrated by the 
observation of high associations (Pearson’s r) between the FAAM 
subscales and the SF- 36 physical function subscale (activities of 
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daily living subscale: 0.84; sports subscale: 0.78) (45) and the 
12- Item Short Form Health Survey physical components sub-
scale (activities of daily living subscale: 0.83; sports subscale: 
0.78) (59). In patients with hallux valgus, a high association was 
observed between the FAAM activities of daily living subscale and 
the Patient- Reported Outcomes Measurement Information Sys-
tem physical function scale (0.70) (60).
Responsiveness. Responsiveness (assessed by using mean 
differences, Guyatt Index, and area under the ROC curves) was eval-
uated in the original publication for a sample of participants (N = 164) 
with leg, ankle, and foot pain. Adequate responsiveness was found for 
the FAAM activities of daily living subscale (mean difference: 17.1 [SD 
19.8]; Guyatt Index: 2.75; ROC: 0.80) and the sports subscale (mean 
difference: 17.2 [SD 24.8]; Guyatt Index: 1.40; ROC: 0.72) (45). In a 
sample of participants with diabetes and a foot or ankle orthopedic 
condition, responsiveness was evaluated at a group level (by using 
analysis of variance) and an individual level (by using area under the 
ROC curves) for the FAAM activities of daily living subscale. Similar 
responsiveness to the original publication was observed (mean differ-
ence: 17.0 [SD 19.0]; ROC: 0.73) (58). Adequate responsiveness was 
reported for the Turkish versions of the FAAM (effect size: 1.40) (53).
Minimally important differences. Minimally important 
differences have been reported from a sample of participants with 
lower- limb musculoskeletal conditions (activities of daily living sub-
scale: 8 points; sports subscale: 9 points) (45), those with dia-
betes (9 points) (58), and those attending a university orthopedic 
clinic (activities of daily living subscale: range between 3 and 25 
points; sports subscale: range between 9 and 77 points, depend-
ing on the method of calculation) (61).
Generalizability. The FAAM was originally developed for 
use in patients with a musculoskeletal condition of the leg, ankle, 
or foot and is therefore generalizable to a variety of patient groups 
and conditions. Psychometric properties have been evaluated 
in both surgical and nonsurgical samples. However, the sports 
subscale may not be relevant for some patient populations, as 
demonstrated by the floor effect in patients with diabetes (58).
Use in clinical trials. The FAAM has been used as an out-
come measure in clinical trials of ankle injuries (62–64), plantar 
heel pain (65–68), taping for exercise- related leg pain (69), and 
edema in patients with ankle/hindfoot fractures (70).
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the FAAM are its availability in 
several languages, its extensive psychometric evaluation (includ-
ing Rasch analysis) in both surgical and nonsurgical samples, and 
its simple administration and scoring.
Caveats and cautions. The use of the FAAM with certain 
patient groups should be considered. Rasch measurement mod-
eling identified that the FAAM activities of daily living subscale 
items 10 (coming up on your toes) and 11 (squatting) may not 
be appropriate to evaluate ankle ability and that the wording may 
need revision (59). Also, a floor effect was identified for the sports 
subscale in patients with diabetes (58).
Clinical usability. The FAAM is a feasible outcome meas-
ure to evaluate physical function in patients with conditions 
affecting the leg, ankle, and foot. The American Physical Ther-
apy Association recommends that the FAAM to be used by 
clinicians to evaluate treatment for plantar heel pain (71). A con-
sensus statement from the International Ankle Consortium rec-
ommended that the FAAM be used to evaluate the efficacy of 
treatments after acute ankle sprain (72).
Research usability. The FAAM is a robust outcome meas-
ure to evaluate physical function in patients with conditions affect-
ing the leg, ankle, and foot. The minimally important differences 
vary depending on the method of calculation, which may impact 
the interpretation of findings.
FOOT AND ANKLE OUTCOME SCORE
Description
Purpose. The FAOS is an adaptation of the Knee Injury and 
Osteoarthritis Outcome Score, which was originally developed in 
1998 to assess short- and long- term patient- relevant outcomes 
following knee injury (73). In 2001, Roos et  al (74) substituted 
“knee” with “foot/ankle” and validated the new tool in 213 in 
patients undergoing surgical reconstruction of lateral ankle liga-
ments. The FAOS has primarily been used as a foot and ankle 
surgical outcome measure.
Content or domains. The FAOS has five foot- health–
related domains: pain (9 items), other symptoms (7 items), activ-
ities of daily living (17 items), sport and recreational activities (5 
items), and foot and ankle- related quality of life (4 items).
Number of items. Forty- two items.
Response options/scale. Five- point Likert scale 
(no, mild, moderate, severe, and extreme).
Recall period for items. One week.
Cost to use. Free.
How to obtain. The formatted questionnaire and user’s 
guide can be downloaded from www.koos.nu. An online calcula-
tor is also available at www.ortho toolk it.com/faos.
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Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. Each item is scored from 0 to 4. Raw subscale 
scores are calculated first by adding each item, and then each 
subscale is converted to a metric from 0 to 100, in which 100 
denotes the most severe condition.
Score interpretation. Subscale scores range from 0 
(representing optimal foot health) to 100 (representing worst foot 
health). Higher scores therefore represent worse foot health (74). 
There are no published normative data.
Respondent time to complete. Ten minutes.
Administrative burden. Calculation of subscale scores 
takes less than 5 minutes per participant.
Translations/adaptations. The FOAS has been trans-
lated into Chinese (75), Danish (76), Dutch (77), German (78), 
Korean (79), Persian (80), Thai (81), and Turkish (82). Arabic, 
Estonian, Finnish, Norwegian, Polish, Portuguese, Brazilian Portu-
guese, Spanish, and Swedish versions are available at www.koos.
nu, although validation is still in progress.
Psychometric information
Floor and ceiling effects. In the original study (74), no floor 
effects were observed, although ceiling effects were evident for the 
pain (34% of patients recording the highest possible score), other 
symptoms (24%), activities of daily living (44%), sport and recrea-
tion (30%), and quality of life (19%) subscales. Ceiling effects were 
also observed in a study of 136 patients undergoing surgery for 
ankle osteoarthritis, in which 29% of patients recorded the highest 
possible score for the sport and recreation subscale (83).
Reliability. Internal consistency (Cronbach’s α) in the 
original study of 213 patients undergoing surgical reconstruc-
tion of lateral ankle ligaments for each subscale was as follows: 
pain, 0.94; other symptoms, 0.88; activities of daily living, 0.97; 
sport and recreation, 0.94; and quality of life, 0.92 (74). Sub-
sequent studies have reported similar findings regarding pain 
(0.81- 0.96), activities of daily living (0.88- 0.97) and sport and 
recreation (0.79- 0.96), although internal consistency is generally 
lower for other symptoms (0.39- 0.86) and quality of life (0.62- 
0.91) (75,79–85).
Test- retest reliability (intraclass correlation coefficients) over 
a 30- day period in 38 patients from the original study was as fol-
lows: pain, 0.78; other symptoms, 0.86; activities of daily living, 
0.70; sport and recreation, 0.85; and quality of life, 0.92 (74). Sub-
sequent studies have reported similarly high test- retest reliability 
for pain (0.76- 0.97), other symptoms (0.63- 0.96), activities of daily 
living (0.70- 0.99), sport and recreation (0.68- 0.99) and quality of 
life (0.70- 0.99) (75–77,79,80,82,84,85).
Validity. Content validity was originally examined by ask-
ing patients to rate the relevance and importance of each item 
on a scale of 1 to 3 and to suggest additional items. All items 
had a mean relevance score above 2.0, and no other items were 
suggested (74). Criterion validity has not been evaluated because 
of the absence of a gold standard measure of foot pain or func-
tion. Construct validity has been demonstrated by the observation 
of moderate associations (Spearman’s ρ or Pearson’s r) between 
FAOS subscale scores and the Karlsson score (0.58- 0.67) (74), 
the Western Ontario and McMaster Universities Osteoarthritis 
Index (pain, 0.49; other symptoms, 0.37; activities of daily living, 
0.52; sport and recreation, 0.45) (84), the AOFAS score (pain, 
0.49; other symptoms, 0.30; activities of daily living, 0.40; sport 
and recreation, 0.43; quality of life, 0.45) (77), the numerical rat-
ing scale for pain (pain, 0.98; other symptoms, 0.63; activities of 
daily living, 0.89; sport and recreation, 0.74; quality of life, 0.66) 
(75), the visual analog pain scale (pain, 0.66- 68; other symptoms, 
0.45- 0.46; activities of daily living, 0.53- 0.62; sport and recrea-
tion 0.46- 0.58; quality of life, 0.50- 0.63) (77,79), and the SF- 36 
physical function (pain, 0.37- 0.72; other symptoms, 0.12- 0.73; 
activities of daily living, 0.46- 0.77; sport and recreation, 0.21- 079; 
quality of life, 0.09- 0.71) (75,77,80–83,85,86), role physical (pain, 
0.28- 0.62; other symptoms, 0.02- 0.59; activities of daily living, 
0.24- 0.64; sport and recreation, 0.18- 0.57; quality of life, 0.05- 
0.72) (75,77,80,81,83,85,86), and bodily pain subscales (pain, 
0.26- 0.78; other symptoms, 0.08- 0.71; activities of daily living, 
0.24- 0.75; sport and recreation, 0.18- 0.67; quality of life, 0.10- 
0.76) (75,77,80–83,85,86). Generally, the construct validity has 
been reported to be lower for the other symptoms and quality of 
life subscales.
Responsiveness. Responsiveness (effect size) in patients 
undergoing hindfoot/ankle surgery and surgery for ankle osteo-
arthritis, hallux valgus, and flatfoot deformity has been shown to 
be moderate to high for the pain (0.51- 1.06) and quality of life 
(0.90- 1.58) subscales and low to high for the activities of daily 
living (0.27- 0.87), other symptoms (0.12- 0.55), and sport and rec-
reation (0.01- 1.02) subscales (83,85–87).
Minimally important differences. Minimally important 
differences for the Dutch version of the FAOS (by using two differ-
ent anchor methods) were reported as follows: pain, 7/13 points; 
other symptoms, 15/13 points; activities of daily living, 18/14 
points; sport and recreation, 23/33 points; and quality of life, 
22/22 points. However, these values varied according to base-
line scores and had large confidence intervals, indicative of poor 
reliability (87).
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Generalizability. Although the FOAS has been evaluated 
in a variety of patient groups and conditions, it has primarily been 
used in surgical studies. Its psychometric properties in nonsurgi-
cal studies are relatively limited.
Use in clinical trials. The FAOS has been used as the 
primary outcome measure in randomized trials of rehabilitation 
(88–90) and surgical repair (91–93) after ankle sprain and in ran-
domized trials of laser treatment (94) and bracing (95) for Achilles 
tendinopathy.
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the FAOS include its broad cov-
erage of five distinct domains of foot health and its availability in 
several languages.
Caveats and cautions. The FAOS items were derived from 
a knee outcome score rather than being specifically developed for 
the foot. This is particularly evident in items 4 (“Can you straighten 
your foot/ankle fully?”) and 5 (“Can you bend your foot/ankle fully?”) 
which are appropriate for the knee but have questionable applica-
bility to the foot. The other symptoms, sports and recreation, and 
quality of life subscales do not perform as well as the pain and activ-
ities of daily living scales in terms of internal consistency, construct 
validity, and responsiveness. Ceiling effects have been observed for 
each subscale, and minimal important differences vary according to 
baseline scores and have large confidence intervals. A Rasch anal-
ysis has not yet been performed on the FAOS, so it is unclear as 
to whether the overall subscale scores summed from each ordinal 
item can be considered linear, interval- level variables (96).
Clinical usability. The FAOS is relatively long compared 
with other scales (42 items) and may therefore be too burden-
some for routine clinical use. An evaluation of the Korean version 
demonstrated that paper and electronic (tablet) formats provided 
equivalent results, although patients found the electronic version 
easier to complete (97).
Research usability. The FAOS was the second most 
commonly used outcome measure in 2015- 2016 (98). However, 
because of several psychometric shortcomings, particularly ceil-
ing effects and the absence of robust minimally important dif-
ference values and Rasch analysis, further development of this 
outcome measure is required before it can be recommended for 
use in clinical trials.
FOOT FUNCTION INDEX–REVISED
Description
Purpose. To evaluate foot- health–related quality of life.
Content or domains. The Foot Function Index (FFI) was 
developed in 1991 to measure the impact of foot pathology on 
function in terms of pain, disability, and activity restriction (99). In 
2006, the FFI was revised (FFI- R) to evaluate four domains: pain 
and stiffness (20 items), difficulty (20 items), activity limitation (9 
items), and social/emotional issues (19 items) (100).
Number of items. There are two versions of the FFI- R, a 
short and long form. The short form contains 34 items, and the 
long form contains 68 items.
Response options/scale. The FFI- R uses a 4- point Likert 
scale from 1 (“no pain,” “no stiffness,” “no difficulty,” and “none of 
the time”) to 4 (“severe pain,” “severe stiffness,” “severe difficulty,” 
“all of the time,” and “most of the time”). A score of 5 can be 
selected for items that are not applicable. The original version of 
the FFI- R used a 6- point Likert scale (100), but this was revised to 
the current 4- point scale in 2013 (101).
Recall period for items. One week.
Cost to use. Free.
How to obtain. The formatted FFI- R short and long forms 
are available in a review article (101).
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. Scores for each subscale are summed then divided 
by the maximum total score for the subscale items that the patient 
indicated were applicable, after which they are multiplied by 100 and 
reported as a percentage. The pain and stiffness subscale scores 
should be combined and reported as a single pain/stiffness score, 
despite the outcome measure indicating that each subscale has 
an individual score. The scoring of pain and stiffness as separate 
subscales was revised during the development of the FFI- R (100).
Score interpretation. Scores range from 0%- 100%, with 
higher scores representing a worse foot function. The long form 
FFI- R can be used to obtain a total score and individual subscale 
scores. The short form FFI- R was developed to obtain a total foot 
function score (100). Normative data have been derived from the 
German version of the FFI but not from the FFI- R (102).
Respondent time to complete. Less than 30 minutes for 
the long form and 10 minutes for the short form.
Administrative burden. Self- study of the scoring docu-
mentation (101).
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Translations/adaptations. The original FFI was revised in 
2006 to the FFI- R. The FFI- R has been adapted to a short form 
(34 items) and a long form (68 items). The FFI- R has been trans-
lated and culturally adapted into Brazilian Portuguese (103), Polish 
(104), and Turkish (105).
Psychometric information
Floor and ceiling effects. A floor effect was demonstrated 
for 4.5% of the sample used to develop the FFI- R (100).
Reliability. Internal consistency was analyzed in the original 
study of 92 patients from a foot arthritis clinic at a Veterans Health 
Administration hospital. A Rasch analysis of the FFI- R total score 
found a person reliability of 0.96 and an item reliability of 0.93. 
The item reliabilities for the subscales were as follows: pain and 
stiffness, 0.93; disability, 0.92; activity limitation, 0.90; and social/
emotional issues, 0.84 (100). For the short form FFI- R, the person 
reliability was 0.95, which suggests the total score of the short 
form FFI- R is similar to the total score for the long form FFI- R. The 
test- retest reliability has not been determined for the FFI- R.
Validity. Content validity of the FFI- R was evaluated by 
using the original FFI, a literature review, interviews with foot spe-
cialists, reviews by foot specialists in a focus group, interviews 
with patients about their experiences, and reactions to completing 
a draft of the FFI- R (100). Criterion validity has not been evaluated 
because of the absence of a gold standard measure of foot pain 
or function. Construct validity has been evaluated by using Rasch 
item maps and the correlation with the time taken to walk 50 ft. 
Rasch item maps found that items of low- severity foot problems 
(eg, standing on tip toes) were found at the bottom (low disabil-
ity) of the item hierarchy. Conversely, items of high severity (eg, 
being bed- bound) were found at the top (high disability) of the item 
hierarchy. Construct validity was also evaluated by correlating the 
FFI- R with a timed 50- ft walk, and a small to moderate correlation 
of 0.31 (P = 0.018) was found (100).
Responsiveness. Responsiveness of the FFI- R was not 
reported in the original article (100). The responsiveness of the 
FFI- R short form (assessed by using Guyatt Index and the SRM) 
was evaluated in a sample of 88 people with first metatarsophalan-
geal joint osteoarthritis (106). The authors reported responsiveness 
by subscale and found that responsiveness ranged from medium 
to very large depending on the method. Responsiveness for each 
subscale is as follows: pain, SRM of 1.05 and Guyatt Index of 
1.73; stiffness, SRM of 0.68 and Guyatt Index of 1.17; and dif-
ficulty, SRM of 0.70 and Guyatt Index of 1.42. The sensitivity to 
change (minimal detectable change) of the FFI- R long form was 
reported in a study that included 30 participants with midfoot pain 
who were evaluated after the use of foot orthoses for 4 weeks 
(107). The changes for each subscale were as follows: pain, 5 
points; stiffness, 6 points; disability, 7 points; activity limitation, 7 
points; social/emotional issues, 7 points; and total score, 5 points.
Minimally important differences. Minimally important 
differences have not been reported for the FFI- R. As discussed 
in the section above, the minimal detectable change has been 
reported in a study that included 30 participants with midfoot pain 
(107).
Generalizability. The FFI- R was developed with patients 
who were predominantly middle- aged (mean of 69 years) men 
with foot arthritis (100). The questionnaire has also been used as 
an outcome measure for surgical studies (108,109).
Use in clinical trials. The FFI- R has been used as an out-
come measure in clinical trials of medial knee osteoarthritis (110), 
first metatarsophalangeal joint osteoarthritis (111), plantar fasciitis 
(67,112,113), and diabetic foot ulcers (114) and has been used to 
evaluate surgical implants (109).
Critical appraisal of overall value to the  
rheumatology community
Strengths. The FFI- R underwent a robust development by 
using Rasch analysis and classical test theory in combination with 
patient and expert clinician interviews. The outcome measure is 
responsive, is easy to administer and score, and is provided in a 
short form (34 items) if users are interested in a total score rather 
than subscale scores.
Caveats and cautions. The validity and reliability of the 
FFI- R has been evaluated in a relatively small sample (N = 92) 
of predominantly middle- aged men. In addition, the psychometric 
properties of this outcome measure have not been independently 
evaluated. Therefore, independent evaluation in a large diverse 
sample would strengthen the validity and reliability. Regarding 
administration and scoring, studies have differentially scored and 
reported the FFI- R. The original study reported the FFI- R to have 
four subscales (pain and stiffness, difficulty, activity limitation, and 
social/emotional issues); however, several studies have reported 
pain and stiffness as separate scales. Similarly, the original article 
reported that the FFI- R short form should only be used to cal-
culate a total score; however, several studies have reported the 
FFI- R short form by subscale (100).
Clinical usability. The FFI- R is a feasible tool for use in 
clinical practice. The time taken to complete the 68 items of the 
long form FFI- R may be somewhat time consuming during clinical 
encounters. However, a total score can be established by using 
the short form (34 items), which is feasible during clinical encoun-
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ters. The lack of robust clinically important difference values limits 
the interpretability of findings in clinical practice.
Research usability. The methods used to develop the 
FFI- R were robust because of the use of Rasch analysis and 
patient and expert interviews. Accordingly, the FFI- R has been 
used in several randomized trials. However, its psychometric prop-
erties require independent evaluation by using a larger and more 
diverse sample than was used for its development.
FOOT HEALTH STATUS QUESTIONNAIRE
Description
Purpose. The FHSQ was developed in 1998 to measure 
foot- health–related quality of life (115,116).
Content or domains. The FHSQ has four foot- health–
related domains: pain (four items), function (four items), footwear 
(three items), and general foot health (two items).
Number of items. Thirteen items.
Response options/scale. Five- point Likert scales.
Recall period for items. One week.
Cost to use. The current price is $129.95 Australian dollars 
(approximately US $90).
How to obtain. The questionnaire and scoring program are 
available from the CareQuest website at www.fhsq.org.
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. There is a dedicated FHSQ software program. 
When less than 50% of the responses for any one scale is miss-
ing, the missing responses are assigned with the average value of 
the completed questions for that scale (116).
Score interpretation. Subscale scores range from 0 (rep-
resenting poorest state of foot health) to 100 (representing optimal 
foot health). Higher scores therefore represent better foot health 
(115,116). There are no published normative data.
Respondent time to complete. Five to 10 minutes.
Administrative burden. Calculation of subscale scores 
by using the software takes less than 5 minutes per participant.
Translations/adaptations. The FHSQ has been trans-
lated and culturally adapted into Brazilian Portuguese (117), 
Danish (118), French (119), Spanish (120), and Valencian (121). 
Turkish, Persian, and Thai versions are also under develop-
ment.
Psychometric information
Floor and ceiling effects. Not reported.
Reliability. Internal consistency (Cronbach’s α) was originally 
reported in 111 podiatry patients as follows: pain, 0.88; function, 
0.86; footwear, 0.85; and general foot health, 0.88 (115). Similar 
internal consistency was observed for the Brazilian Portuguese 
(pain, 0.68; function, 0.81; footwear, 0.82; and general foot health, 
0.76) (117) and French (pain, 0.90; function, 0.90) (119) versions. 
Test- retest reliability (intraclass correlation coefficients) was origi-
nally reported in 72 patients who completed the survey before and 
after a week of routine care: pain, 0.86; function, 0.92; footwear, 
0.74; and general foot health, 0.78 (115), and similar reliability was 
observed by using the French version over a 2- day period (pain, 
0.98; function, 0.96) (119).
Validity. Content validity was demonstrated in the original 
publication by noting that individuals with minor foot complaints 
(such as superficial skin conditions) produced higher scores on 
all FHSQ subscales (indicating better health status) compared 
with individuals with more severe musculoskeletal foot problems 
(115). Similarly, in a study of 784 older people, the FHSQ foot 
function scales were shown to differ between those with minor 
skin or nail problems (mean score 89), structural deformity (mean 
score 78), and acute foot disease (average score 54) (122). Cri-
terion validity has not been evaluated because of the absence 
of a gold standard measure of foot pain or function. Construct 
validity has been demonstrated by the observation of moderate 
associations (Pearson’s r) between FHSQ subscale scores and 
the visual analog pain scale (pain, −0.40 to −0.52; function, 
−0.45 to −0.51) (118,119), numerical rating scale (pain, −0.85; 
function, −0.60) (117), Health Assessment Questionnaire (pain, 
−0.43; function, −0.64) (117), and EuroQOL 5D (pain, −0.45; 
function, −0.58) (120).
Responsiveness. High responsiveness (assessed by using 
Guyatt Index) was reported in a sample of 59 older people who 
received extra- depth footwear to treat their foot pain over a 16- 
week period for the pain (1.70) and function (1.22) subscales, but 
responsiveness of the footwear (0.21) and general foot health 
(0.68) subscales was lower (123). Similarly, in a sample of 88 peo-
ple with first metatarsophalangeal joint osteoarthritis who received 
rocker- sole footwear or foot orthoses over a 12- week period, high 
responsiveness was observed for the pain (1.30) and function 
(1.23) subscales (106).
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Minimally important differences. Minimally important 
differences have been reported in several participant groups, 
including individuals with plantar heel pain (pain, 13 points; func-
tion, 7 points; footwear, 2 points; general foot health, 0 points) 
(124), older people with foot pain (pain, 12 points; function, 10 
points; footwear, 1 point; general foot health, 10 points) (123), and 
individuals with first metatarsophalangeal joint osteoarthritis (pain, 
11 points; function, 10 points) (106).
Generalizability. The FHSQ has broad generalizability 
across a wide range of conditions and participant groups.
Use in clinical trials. The FHSQ has been widely used as 
an outcome measure in clinical trials of treatments for nonspe-
cific foot pain (123,125), plantar heel pain (126–131), first meta-
tarsophalangeal joint osteoarthritis (111,132), interdigital neuroma 
(133), pes cavus (134), and rheumatoid arthritis (135).
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the FHSQ include its coverage 
of four distinct domains of foot health (pain, function, footwear, 
and general foot health), its substantial psychometric evaluation, 
its availability in several languages, responsiveness of the pain and 
function subscales, and ease of completion and scoring.
Caveats and cautions. The sample on which the origi-
nal factor analysis was performed was relatively small (N = 225), 
and it has been argued that the factors are not sufficiently dis-
tinct and may therefore contain some redundant items (136). A 
Rasch analysis has not yet been performed on the FHSQ, so it is 
unclear as to whether the overall subscale scores summed from 
each ordinal item can be considered linear, interval- level variables 
(96). The FHSQ footwear and general foot health subscales do not 
appear to perform as well as the pain and function subscales in 
terms of reliability and responsiveness.
Clinical usability. Because of the ease of completion and 
scoring, routine clinical administration of the FHSQ is feasible, and 
it has been used in several audit studies to document patient out-
comes, particularly following foot surgery (137,138). An analysis of 
readability found that the FHSQ is suitable for patients with at least 
seventh- grade reading skills (139).
Research usability. The FHSQ is one of the most com-
monly used outcome measures in randomized clinical trials 
because of its relatively robust psychometric profile, its respon-
siveness, and the availability of minimally important difference val-
ues across a range of foot conditions and patient populations. 
Further investigation is required to evaluate floor and ceiling effects 
and to perform Rasch analysis.
LEEDS FOOT IMPACT SCALE FOR RHEUMATOID 
ARTHRITIS
Description
Purpose. The LFIS- RA was developed in 2005 to evaluate 
the efficacy of multidisciplinary foot-health care in rheumatoid 
arthritis, both for routine clinical purposes and for research (140).
Content or domains. There are two subscales: impair-
ment/footwear (21 items) and activity limitation/participation 
restriction (30 items).
Number of items. Fifty- one items.
Response options/scale. “True” and “not true.”
Recall period for items. At the moment.
Cost to use. Free.
How to obtain. The LFIS- RA can be viewed in an appendix 
to an article describing its translation and cross- cultural validation 
for use in four European languages (141). Users are required to 
register use with the University of Leeds (Leeds, UK) at https://
eprov ide.mapi-trust.org/instr ument s/leeds-foot-impact-scale-for-
rheum atoir-arthr istis.
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. A “true” response is scored as 1 point, and a “not 
true” response is scored as 0. Item scores in each subscale are 
then totaled to provide separate subscale scores that can be sum-
mated to provide an overall score (maximum overall score of 51).
Score interpretation. A higher score indicates greater 
disability. A score of greater than 7 on the impairment/footwear 
subscale indicates moderate to high levels of foot impairment, 
and a score greater than 10 on the activity limitation/participation 
restriction subscale indicates moderate to high levels of foot dis-
ability (142).
Respondent time to complete. Not reported.
Administrative burden. Self- study of the scoring docu-
mentation (140).
Translations/adaptations. The LFIS- RA has been trans-
lated and culturally adapted into Dutch, German, and Hungarian 
(141,143).
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Psychometric information
Floor and ceiling effects. No floor or ceiling effects were 
observed for the LFIS- RA in a study of 30 people with rheumatoid 
arthritis (144).
Reliability. Test- retest reliability (intraclass correlation coeffi-
cients) over a 2- week period in the original study was 0.84 for the 
impairment/footwear subscale and 0.96 for the activity limitation/
participation restriction subscale (140).
Validity. Candidate questionnaire items were derived 
from qualitative interviews with patients with rheumatoid arthritis 
and foot problems and then tested by patients with rheumatoid 
arthritis in the presence of an interviewer, ensuring content valid-
ity (140). Selection of the final subscale items was performed by 
fitting them to the Rasch unidimensional measurement model. 
The 21 items in the final impairment/footwear subscale dis-
played a good fit to the Rasch model and no significant devia-
tion from model expectation across the trait (overall mean item 
of −0.25 [SD 1.07], mean person of −0.34 [SD 0.71], and item- 
trait interaction χ2 statistic of 45.07; P = 0.35 [42 degrees of 
freedom]). Similarly, the 30 items in the activity limitation/partic-
ipation restriction subscale had a good fit to the Rasch model, 
with no significant deviation from model expectation (over-
all mean item of −0.38 [SD 0.93], mean person of −0.29 [SD 
0.80], and item- trait interaction χ2 statistic of 64.4; P = 0.18 
[60 degrees of freedom]). Neither scale showed differential item 
function for age, sex,or disease duration. Person separation 
was 0.808 for the impairment/footwear subscale and 0.908 for 
the activity limitation/participation restriction subscale, indicat-
ing the ability to discriminate groups of patients. Furthermore, 
scores for both subscales showed highly significant differences 
between groups of patients categorized into quartiles accord-
ing to their scores for the MFPDI, FFI, and Health Assessment 
Questionnaire. However, the original validation did not include 
strict tests of unidimensionality. In a subsequent adaptation and 
cross- cultural validation study, the original UK version demon-
strated multidimensionality and limited fit to the Rasch model, 
but adaptation satisfactorily resolved these violations of the 
Rasch model (141).
Responsiveness. A study of 30 patients with rheumatoid 
arthritis undergoing foot surgery found that the LFIS- RA was 
less responsive than the FFI (144). Over a mean follow- up of 
38 months, the within- group standard effect size for the LFIS- RA 
was 0.58, the SRM was 0.58, and Guyatt Index was 0.90, indicat-
ing moderate internal responsiveness. In relation to being much 
improved or very much improved on an anchor question about 
change since surgery, the area under the curve within the ROC 
curve was 0.656 and the optimal cutoff point was 1.5 points, with 
a sensitivity of 75% and specificity of 57%.
Minimally important differences. Minimally important 
differences have not been reported for the LFIS- RA.
Generalizability. The LFIS- RA was developed for use in 
rheumatoid arthritis. It has been used in patients with psoriatic 
arthritis (5,145), gout (146–149), and systemic lupus erythemato-
sus (150), although its psychometric properties in conditions other 
than rheumatoid arthritis have not been evaluated.
Use in clinical trials. The LFIS- RA has been used as an 
outcome measure in clinical trials of podiatry care and footwear 
and orthoses interventions in rheumatoid arthritis and gout (151–
153).
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the LFIS- RA include its empha-
sis on footwear, its broad coverage of other issues related to foot 
health in rheumatoid arthritis (impairments, activity limitation, and 
participation), and its availability in several languages.
Caveats and cautions. The LFIS- RA was developed for 
use in rheumatoid arthritis. Although it has been used in diseases 
other than rheumatoid arthritis, its psychometric properties for 
these conditions has not been evaluated. There are limited data 
on its responsiveness, and minimal important differences have not 
been reported.
Clinical usability. Although it was designed for use for 
both clinical and research purposes, the LFIS- RA is the second 
longest instrument included in this review and may therefore be 
time consuming to use during clinical encounters. Its interpret-
ability in clinical practice is limited by the lack of robust clinically 
important difference values.
Research usability. The original validation of the LFIS- RA 
suggested that it is valid and reliable. However, further inde-
pendent evaluation of its psychometric properties, including its 
responsiveness, the assessment of minimally important difference 
values, and its performance in diseases other than rheumatoid 
arthritis, is required.
MANCHESTER FOOT PAIN AND DISABILITY 
INDEX
Description
Purpose. The MFPDI was developed in 2000 for use in a 
population survey and aimed to be sufficiently sensitive to identify 
a range of disabilities associated with foot pain (154).
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Content or domains. Its original validation identified 
three domains: pain intensity (5 items), functional limitation (10 
items), and personal appearance (2 items) (154). Two additional 
items about work and leisure activities were excluded from this 
analysis because they were thought not to be relevant to all 
people. Subsequently, independent exploratory factor analyses 
undertaken in separate populations identified different factor 
structures. Menz et al (155) identified four domains: functional 
limitation (seven items), activity restriction (two items), pain 
intensity (six items), and personal appearance (two items). 
Cook et al (156) found two domains: foot and ankle function 
(nine items) and pain and appearance (seven items), with one 
item removed. In a confirmatory factor analysis investigating 
the suitability of these three different factor structures, the orig-
inal three- factor structure performed best (157). Non- English 
language versions have identified further different factor struc-
tures.
Number of items. Nineteen items.
Response options/scale. Items are reported as occurring 
none of the time, on some days, or on most days/every day.
Recall period for items. One month.
Cost to use. The license fee depends on whether the use is 
for a commercial or an academic study, on the number of times 
the measure is to be used, on language requirements, and on 
whether the user manual is required.
How to obtain. The MFPDI can be viewed in an appendix 
to the original article (154). A license to access the questionnaire 
and user manual should be requested from Oxford University 
Innovation at https://innov ation.ox.ac.uk.
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. In the original description, it was stated that indi-
vidual subscale (domain) scores could be derived to produce 
an overall disability measure (154), although scoring was not 
described. Various authors have allocated different scores to item 
responses to produce total and individual domain scores: “none 
of the time” = 0 or 1, “on some days” = 1 or 2, and “on most days/
every day” = 2 or 3, so the total score ranges from 0 to 34 or 17 to 
51 depending on which scoring is used (155,156,158,159).
Score interpretation. Higher scores indicate worse foot 
pain/disability. The Rasch unidimensional measurement model 
has shown that the function and pain subscales are unidimen-
sional, and interval- level scores can be obtained (160). A categor-
ical definition of disabling foot pain (present/absent) can also be 
derived. Garrow et al (158) defined disabling foot pain as a prob-
lem occurring on at least 1 of the 17 pain, function, or appear-
ance items on at least some days in the last month. It has been 
argued that this cutoff is too infrequent for “disabling” foot pain, 
which should be defined by using only the functional limitation 
items without the pain intensity and personal appearance items. 
An alternative definition requiring a problem to occur on at least 1 
of the 10 functional limitation items on most days/every day in the 
last month has been validated (157).
Respondent time to complete. Not reported.
Administrative burden. Self- study of the scoring docu-
mentation (154).
Translations/adaptations. The MFPDI has been trans-
lated and culturally adapted into Greek (161), Portuguese (162), 
Spanish (163), Danish (164), Dutch (165), and Chinese (166).
Psychometric information
Floor and ceiling effects. Neither floor nor ceiling effects 
were examined in the original study (154). When using the Dutch 
translation in a clinical trial in people with forefoot problems, 
investigators observed no floor or ceiling effects for the pain and 
function subscales (165). The lowest possible score (0 or 1) was 
scored by 7.4% and 8.8% of participants for the pain and function 
subscales, respectively.
Reliability. Internal consistency (Cronbach’s α) was 0.99 
(19 items) in the original validation (154) and 0.89 (17 items) in the 
subsequent evaluation by Menz et al (155). Cronbach’s α values 
of 0.74, 0.92, and 0.77 have been reported for the pain intensity, 
functional limitation, and appearance domains, respectively (157).
Test- retest repeatability for disabling foot pain was poor for 
pain intensity, fair for functional limitation, and good for appear-
ance (κ = 0.34, 0.57, and 0.61, respectively) when problems were 
required to occur on at least some days in the last month, and 
it was fair for pain intensity (0.55), good for functional limitation 
(0.72), and poor for appearance (0.34) at the more stringent cutoff 
of most days/every day (157).
Validity. Content validity was achieved by interviewing 
patients attending foot clinics about pain, disability, activity limi-
tation, and footwear (154). The proportion reporting disability was 
highest for participants consulting a rheumatologist, followed by 
those consulting their general practitioner and then population 
survey respondents; among the latter, the proportion was higher 
in those who had consulted a health care professional than in 
those who had not, demonstrating construct validity. Criterion 
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validity has not been evaluated because of the absence of a gold 
standard measure of foot pain or function. Construct validity was 
demonstrated subsequently by the observation of lower median 
SF- 36 physical function subscale scores in those reporting prob-
lems in the functional limitations domain (157). Menz et al (155) 
identified associations between disabling foot pain and lower arch 
height, and between disabling foot pain and less ankle joint motion 
as well as correlations (Pearson’s r) between MFPDI scores and 
the Goldberg Anxiety and Depression Scale depression subscale 
(total, 0.34; pain intensity, 0.23; functional limitation, 0.32; appear-
ance, 0.28) and the SF- 36 mental health (functional limitation, 
0.20) and general health (activity limitation, 0.21) subscales.
Responsiveness. Responsiveness (effect size) over 16 
weeks in a randomized trial of extra- depth footwear in Australian 
veterans with persistent, disabling foot pain was small for pain 
(0.21) and functional limitation (0.34) and negligible for personal 
appearance (0.08) (123). In the Dutch translation study, respon-
siveness was moderate, with only one of seven a priori stated 
hypotheses about correlations between change in MFPDI sub-
scales and other foot pain outcome measures being met and with 
correlation with a global perceived effect question not reaching an 
acceptable level (r < 0.5) (165).
Minimally important differences. Only one study has 
attempted to evaluate a minimal important change (MIC) (165). 
However, the MFPDI was not responsive enough to calculate an 
MIC.
Generalizability. The MFPDI was designed for use in a 
population survey. It was developed and validated in people with 
varying foot health profiles attending rheumatology clinics, con-
sulting with their general practitioner, or responding to a postal 
population survey (154). Its psychometric properties have been 
evaluated subsequently in community- dwelling adults across the 
age range (155–157,161), in people consulting with clinical ser-
vices about foot problems (163,164,166), and in participants in 
clinical trials (123,165).
Use in clinical trials. The MFPDI has been used as an out-
come measure in clinical trials in forefoot problems (165), Morton 
neuroma (167,168), plantar callosities/corns (169,170), plantar 
heel pain (171), osteoporosis (172), midfoot osteoarthritis (173), 
and systemic sclerosis (174) and in older people with foot pain or 
foot problems (159,175,176).
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the MFPDI include its coverage 
of multiple distinct domains of foot health, its availability in several 
languages, its psychometric evaluation (including Rasch analysis), 
and it being short and easily administered and scored. It is also 
suitable for use in population surveys and can generate both foot 
pain/disability scores and a categorical definition of disabling foot 
pain.
Caveats and cautions. Several different domain struc-
tures have been proposed, and uncertainty remains over 
the most appropriate structure. The original three- factor structure 
is the most commonly used. There has been debate concerning 
the inclusion of foot problems occurring only on some days in 
the categorical definition of disabling foot pain. Its responsiveness 
appears to be limited, and as yet, a minimal important difference 
has not been calculated.
Clinical usability. The MFPDI is short and easily com-
pleted and could be feasible to use in clinical practice. However, 
limited responsiveness and lack of a robust clinically important dif-
ference may impair its interpretability.
Research usability. The MFPDI has been widely used in 
population surveys and is particularly valuable in observational 
studies requiring a case definition for disabling foot pain. Although 
it has been used in several clinical trials, further investigation of 
its responsiveness and minimally important difference values is 
required.
MANCHESTER- OXFORD FOOT QUESTIONNAIRE
Description
Purpose. The MOXFQ is derived from the MFPDI (154) and 
was originally developed in 2006 as an outcome measure for 
hallux valgus surgery (177). It has recently been amended and 
validated for use among patients with a variety of foot or ankle 
problems (178).
Content or domains. The MOXFQ has three foot- 
health–related domains: walking/standing problems (seven 
items), pain (five items), and issues related to social interaction 
(four items). An overall summary index score can also be cal-
culated (179).
Number of items. Sixteen items.
Response options/scale. Five- point Likert scales.
Recall period for items. Four weeks.
Cost to use. The license fee depends on whether the use is 
for a commercial or an academic study, on the number of times 
the measure is to be used, on the language requirements, and on 
whether the user manual is required.
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How to obtain. A license to access the questionnaire and 
user manual can be requested from Oxford University Innovation 
at https://innov ation.ox.ac.uk.
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. Each item is scored from 0 to 4, with 4 denot-
ing most severe. Raw scale scores are then each converted to 
a metric from 0 to 100, in which 100 denotes the most severe 
(177). The summary index score is simply calculated as the sum of 
the three subscale scores and is also converted to a metric from 
0 to 100 (179).
Score interpretation. Subscale scores and the summary 
index score range from 0 (representing optimal foot health) to 100 
(representing worst foot health). Higher scores therefore represent 
worse foot health (177). There are no published normative data.
Respondent time to complete. Five to 10 minutes.
Administrative burden. Calculation of subscale scores 
takes less than 5 minutes per participant.
Translations/adaptations. The MOXFQ has been trans-
lated and culturally adapted into Chinese (180), Dutch (181), 
German (182), Italian (183), Korean (184), Persian (185), Span-
ish (186), and Turkish (187). Danish, Finnish, Welsh, Lithuanian, 
Norwegian, and French versions are also available from Oxford 
University Innovation.
Psychometric information
Floor and ceiling effects. In the original study, no items 
exhibited a ceiling effect, but 2 items on the 20- item scale exhib-
ited a floor effect and were therefore excluded from the final 16- 
item version (177). Subsequent studies using the 16- item scale 
have generally shown floor and ceiling effects of less than 15% 
(178,182,185,186,188). However, the Spanish version exhibited a 
20% ceiling effect for the walking/standing subscale because more 
than 50% of participants selected the highest score option for 
items 2 through 6 (186).
Reliability. Internal consistency (Cronbach’s α) in the orig-
inal study of 100 patients undergoing hallux valgus surgery for 
each subscale was as follows: walking/standing, 0.92; foot pain, 
0.86; and social interaction, 0.73 (177). Similar results were sub-
sequently observed in the translated versions, with the range of 
Cronbach’s α for each subscale as follows: walking/standing, 
0.77 to 0.99; pain, 0.78 to 0.98; and social interaction, 0.70 to 
0.99 (180–188). Test- retest reliability (intraclass correlation coeffi-
cients) in 257 patients undergoing various foot and ankle surgical 
procedures for each subscale has been reported as follows: walk-
ing/standing, 0.96; pain, 0.94; and social interaction, 0.92 (178). 
Across the various language translations, test- retest reliability has 
been reported as follows: walking/standing, 0.82 to 0.97; pain, 
0.81 to 0.98; and social interaction, 0.82 to 0.96 (180–188).
Validity. Content validity was originally examined by 
using exploratory, semistructured interviews conducted with 10 
patients who were attending hospital surgical outpatient clinics 
for hallux valgus, followed by patients completing and com-
menting on the MFPDI. This resulted in the rewording of some 
MFPDI items, the addition of two items specifically addressing 
pain severity and pain frequency at nighttime, and the increasing 
of the response categories from three to five per item (177). Crite-
rion validity has not been evaluated because of the absence of a 
gold standard measure of foot pain or function. Construct validity 
has been demonstrated by the observation of moderate asso-
ciations (Spearman’s ρ) between MOXFQ subscale scores and 
the AOFAS score (walking/standing, 0.47- 0.56; pain, 0.37- 0.60; 
and social interaction, 0.29- 48) (177,186,188); the SF- 36 physi-
cal functioning (walking/standing, 0.53- 73; pain, 0.39- 0.66; and 
social interaction, 0.31- 0.68), role physical (walking/standing, 
0.30- 0.64; pain, 0.35- 0.66; and social interaction, 0.31- 0.63), 
and bodily pain (walking/standing, 0.32- 0.71; pain, 0.36- 0.69; 
and social interaction, 0.27- 0.70) subscales (180–188); the FFI 
(walking/standing, 0.70; pain, 0.71; and social interaction, 0.43) 
(180); and the EuroQOL 5D (walking/standing, 0.70; pain, 0.71; 
and social interaction, 0.63) (180).
Responsiveness. In the original validation sample of 100 
patients undergoing hallux valgus surgery, responsiveness at 
12 months (calculated by using effect sizes) was as follows: walk-
ing/standing, 1.12; pain, 1.57; and social interaction, 1.52 (177). 
More recently, similar responsiveness at 6 to 12 months has been 
reported in patients undergoing a range of foot and ankle surgical 
procedures: walking/standing, 0.86 to 2.60; pain, 1.10 to 2.30; 
and social interaction, 0.80 to 2.10 (186,188–190).
Minimally important differences. Minimally impor-
tant differences in 91 patients undergoing hallux valgus surgery 
have been reported for each of the subscales as follows: walk-
ing/standing, 16 points; pain, 12 points; and social interaction, 
24 points (25). In 671 patients undergoing a range of foot and 
ankle surgical procedures, minimally important differences were 
reported as follows: walking/standing, 16 points; pain, 10 points; 
and social interaction, 9 points (191).
Generalizability. Although the original MOXFQ was 
focused on evaluating the outcomes of hallux valgus surgery 
(177), it has also been found to be a useful outcome measure for 
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other types of foot surgery (178,188). Its application in nonsurgical 
studies, however, has not been as thoroughly examined.
Use in clinical trials. The MOXFQ has been used as an 
outcome measure in clinical trials of various injection therapies for 
neuroma (192) and plantar heel pain (193,194), in clinical trials of 
bracing for ankle fracture (195), and in clinical trials of surgery for 
hallux valgus (40) and ankle osteoarthritis (196).
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the MOXFQ include its cov-
erage of three distinct domains of foot health (walking/stand-
ing, pain, and social interaction), its extensive psychometric 
evaluation, its availability in several languages, its high test- 
retest reliability and responsiveness, and ease of completion 
and scoring.
Caveats and cautions. The social interaction subscale 
does not perform as well as the walking/standing and pain sub-
scales in terms of internal consistency, test- retest reliability, and 
responsiveness. Footwear difficulties are limited to one item (“I feel 
self- conscious about the shoes I have to wear”), which may not 
reflect broader footwear issues related to foot problems.
Clinical usability. The MOXFQ is a feasible tool for use in 
clinical practice (189) and has been endorsed by the British Ortho-
paedic Foot and Ankle Society and the College of Podiatry (UK) as 
a standard instrument for assessing patient- reported outcomes 
after foot surgery (197). An analysis of readability has found that 
the MOXFQ is suitable for patients with at least fifth- grade level 
reading skills (139).
Research usability. The MOXFQ has been demonstrated 
to be an excellent tool for the evaluation of foot surgery outcomes, 
particularly hallux valgus, because it has a robust psychometric 
profile, has high test- retest reliability, and is highly responsive. Fur-
ther development is required to assess its performance in nonsur-
gical studies.
SELF- REPORTED FOOT AND ANKLE SCORE
Description
Purpose. The SEFAS is a patient- reported foot- and ankle- 
specific questionnaire adapted in 2012 (198) from the New Zea-
land Total Ankle Replacement Questionnaire (199), which was 
originally derived from the Oxford- 12 Total Hip Replacement 
Questionnaire (200).
Content or domains. The SEFAS questionnaire assesses 
different constructs, including pain, function, limitation of function, 
and other symptoms, that are not separated into domains (198).
Number of items. Twelve items.
Response options/scale. Five- point Likert scales: specific 
responses vary across items.
Recall period for items. Not stated.
Cost to use. Free.
How to obtain. The formatted questionnaire can be down-
loaded from http://www.sweda nkle.se/.
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. Each item is scored from 0 to 4, in which 0 denotes 
the most severe and 4 denotes the least severe. Item scores are 
then summated to range between 0 and 48.
Score interpretation. The final score ranges between 0 
and 48, in which 0 represents the most severe disability and 48 
represents normal function (198). Age- and sex- specific norma-
tive data in 779 healthy people aged 20 to 89 years have been 
published (201).
Respondent time to complete. Three minutes (19).
Administrative burden. Calculation of the final score 
takes less than 5 minutes per participant.
Translations/adaptations. The SEFAS exists as an Eng-
lish and Swedish version (198). It has been adapted into German 
(202) and Norwegian (203) versions.
Psychometric information
Floor and ceiling effects. The SEFAS does not demon-
strate floor or ceiling effects. In the original study, the Swed-
ish SEFAS was administered to 135 individuals with ankle 
osteoarthritis undergoing ankle surgery and demonstrated no 
floor or ceiling effects (198). This was confirmed in a subsequent 
study of 118 individuals with forefoot disorders and 106 individu-
als with midfoot, hindfoot, and ankle disorders (204). These find-
ings have been supported for the German SEFAS (202).
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Reliability. In the original study using the Swedish SEFAS 
total score, internal consistency (Cronbach’s α) was evaluated in 
62 individuals with forefoot disorders and was 0.96 (198). Sim-
ilar findings were reported in a subsequent study of individuals 
with forefoot and midfoot, hindfoot, and ankle disorders (Cron-
bach’s α = 0.84 and 0.86, respectively) (204).These findings were 
confirmed by using the German SEFAS total score (Cronbach’s 
α = 0.89) (202) and the Norwegian SEFAS total score (Cronbach’s 
α = 0.93) (203). Test- retest reliability (intraclass correlation coef-
ficients) of the SEFAS total score has been reported as follows: 
Swedish SEFAS, 0.92 to 0.93 (198,204); German SEFAS, 0.97 
(202); and Norwegian SEFAS, 0.93 (203).
Validity. Content validity was determined by asking a group 
of orthopedic surgeons, physical therapists, and nurses, as well 
as 10 patients, to review the items and provide feedback, includ-
ing the need to revise, exclude, or add items. Minor revisions 
were made to the items; no items were excluded or added. A 
separate group of 40 patients with forefoot disorders were then 
asked to rate the importance of each item from a scale of 1 to 
3, in which 1 represented an unimportant item, 2 represented 
an important item, and 3 represented a highly important item. 
Items with a mean score of 2 or greater were considered rele-
vant. Item scores ranged from 2.0 to 2.8 (mean score 2.6), indi-
cating good construct validity (204). Criterion validity has not been 
examined because of the absence of a gold standard measure of 
foot and ankle pain and function. Construct (convergent) validity 
has been demonstrated by the observation of moderate associ-
ations (greater than or equal to 0.4; Spearman’s ρ or Pearson’s 
r) between the SEFAS total score and several outcome meas-
ures. The SEFAS total score has a moderate association with 
domains of FAOS: pain, 0.82 to 0.83; other symptoms, 0.50 to 
0.70; activities of daily living, 0.68 to 0.77; sport and recreational 
activities, 0.42 to 0.62; and quality of life, 0.67 to 0.82 (198,204). 
Moderate associations have been found for the MOXFQ walk-
ing/standing problems (0.73), pain (0.73), and issues related to 
social interaction (0.57) domains and the summary score (0.77) 
(188). Moderate associations have been found for the SF- 36 
physical functioning (0.64- 0.72), role physical (0.30- 0.44), bodily 
pain (0.71- 0.76), vitality (0.46- 0.52), and social functioning (0.39- 
0.51) domains and the physical component summary score (0.51) 
(198,204). Finally, moderate associations have been found for the 
EuroQOL 5D index score (0.53- 0.76) and the VAS score (0.41- 
0.65) (198,204).
Responsiveness. Responsiveness (6 months, calculated 
with the effect size and SRM) of the Swedish SEFAS total score 
was evaluated in 35 individuals with ankle osteoarthritis under-
going replacement or fusion and was 1.44 and 1.00, respec-
tively (198). Additionally, the responsiveness (6 months) of the 
Swedish SEFAS was evaluated in 66 individuals with forefoot 
disorders and 70 individuals with midfoot, hindfoot, and ankle 
disorders undergoing surgery (204). The effect size and SRM 
were 1.29 and 1.27, respectively, for the forefoot disorders 
group and 1.05 and 0.99, respectively, for the midfoot, hindfoot, 
and ankle disorders group. Responsiveness (6 months) of the 
German SEFAS total score was determined by using 177 indi-
viduals undergoing foot and/or ankle surgery for musculoskeletal 
disorders, and lower responsiveness was reported (effect size 
0.71; SRM 0.65) (202).
Minimally important differences. The minimally impor-
tant difference for the Swedish SEFAS calculated in 163 patients 
undergoing a range of foot and ankle surgical procedures by using 
an anchor- based approach has been reported to be 5 points 
(205).
Generalizability. The SEFAS was originally developed and 
validated in individuals undergoing total replacement or fusion sur-
gery for disorders of the ankle (198), but its psychometric prop-
erties have also been evaluated in individuals undergoing foot 
surgery (188,202,204). Its application in nonsurgical studies has 
not been rigorously examined.
Use in clinical trials. The SEFAS has not been used in any 
randomized trials. However, it has been used in studies investigat-
ing clinical improvement following surgery for hallux valgus (206), 
posterior tibial tendon dysfunction (207), ankle joint disorders 
(208), and ankle fractures (209,210) as well as studies investigat-
ing clinical improvement following ankle fusion and replacement 
(211). The SEFAS has also been used in studies evaluating clinical 
improvement following corticosteroid injection for midfoot osteo-
arthritis (212).
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the SEFAS include it being 
designed for a range of foot and ankle disorders; it being freely 
available, fast to administer, and easy to score; its substantial psy-
chometric evaluation (by using the total score rather than separate 
domains); and its availability in several languages.
Caveats and cautions. The SEFAS questionnaire assesses 
different constructs, including pain, function, limitation of function, 
and other symptoms, but these were not separated into domains 
when it was originally developed, and a psychometric evaluation 
of these domains was not performed (198,204). Psychometric 
evaluation has not occurred for the English version of the SEFAS. 
Further psychometric evaluation has primarily occurred in individ-
uals awaiting foot and/or ankle surgery, so the generalizability is 
limited. Finally, a Rasch analysis has not yet been undertaken.
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Clinical usability. The SEFAS is a feasible outcome for 
use in clinical practice. It is simple and efficient to administer and 
score. However, a significant limitation is that the items that con-
tribute to its domains were not clearly defined when it was origi-
nally developed.
Research usability. The psychometric properties of the 
English SEFAS requires further investigation. Additionally, although 
the total score of the SEFAS (non- English) has undergone sub-
stantial psychometric evaluation, the psychometric properties of 
its domains have not been evaluated.
VISUAL ANALOG SCALE–FOOT AND ANKLE
Description
Purpose. The VAS- FA was developed in 2006 to evaluate 
the effectiveness of surgical and nonsurgical interventions for foot 
and ankle disorders (213).
Content or domains. The VAS- FA questionnaire assesses 
three domains: pain (4 items), function (11 items), and other com-
plaints (5 items) (213).
Number of items. Twenty items.
Response options/scale. VAS (0- 100 mm).
Recall period for items. The wording of the items does 
not specify a recall period. However, participants can be provided 
with instructions to respond to the items referring to one of three 
options: 1) the period before the accident/surgery, 2) the period 
between the accident/surgery and implant removal, or 3) the 
period since implant removal.
Cost to use. Free.
How to obtain. The VAS- FA instructions and score form 
can downloaded from https://www.krank enhaus-rumme lsberg.
de/fuss-und-sprun ggele nkchi rurgi e/spezi elle-metho den-impla 
ntate/ visual-analog-skala-fuss-und-sprun ggele nk-vas-fa/.
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. Each item is scored by using a VAS that ranges from 
0 to 100, in which 0 denotes the most severe and 100 denotes 
the least severe. The scores from each item are summated, and 
this value is then divided by 20, resulting in a possible total score 
ranging from 0 to 100. To obtain scores for each domain, the 
summated scores for the items that make up each domain (pain, 
4 items; function, 11 items; other complaints, 5 items) are divided 
by the number of items for that domain. When there are missing 
responses to items, the developers recommend dividing the sum-
mated score by the number of remaining items (213).
Score interpretation. The total score ranges from 0 to 
100. Each domain score also ranges from 0 to 100. A score of 
0 (for the total score or each domain) represents the most severe 
state, and 100 represents the least severe state. Normative data 
from 121 healthy individuals have been published (214).
Respondent time to complete. Respondent time to 
complete is reported to range from 20 seconds to 6 minutes 
(213,215).
Administrative burden. Thirty seconds when using the 
evaluation matrix provided on the website (213).
Translations/adaptations. The VAS- FA was originally 
presented as a German version with the English translation pro-
vided (213) and has subsequently been translated and culturally 
adapted into Finnish (216), Indian (Malayalam language) (217), 
Thai (215), and Turkish (218).
Psychometric information
Floor and ceiling effects. No floor or ceiling effects have 
been reported for the total score of the Thai VAS- FA (215) or the 
total and domain scores of the Finnish VAS- FA (216). However, 
several items within each domain (Finnish VAS- FA) have been 
reported to demonstrate ceiling effects (216).
Reliability. Internal consistency (Cronbach’s α) of the Thai 
VAS- FA has been reported for the total score as greater than 0.99. 
Additionally, internal consistency (Cronbach’s α) of the Turkish 
VAS- FA total and domain scores has been reported for individuals 
with foot pain (0.75- 0.92) and without foot pain (0.93- 0.96) (218). 
Finally, internal consistency (Cronbach’s α) of the Finnish VAS- FA 
total and domain scores was evaluated in 165 individuals who had 
undergone foot and/or ankle surgery and was reported as follows: 
total, 0.96; pain, 0.91; function, 0.94; and other complaints, 0.81 
(216).
Test- retest reliability of the total score of the Thai VAS- FA in 
42 individuals has been reported as 0.99 (95% confidence interval 
[CI] 0.99- 1.00) (215). In addition, test- retest reliability (intraclass 
correlation coefficients) of the Turkish VAS- FA in 128 individuals 
(63 with foot disorders and 65 asymptomatic individuals) for the 
total score and each domain score has been reported as follows: 
total, 0.93 (95% CI 0.90- 0.96); pain, 0.88 (95% CI 0.819- 0.928); 
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function, 0.88 (95% CI 0.82- 0.93); and other, 0.93 (95% CI 0.90- 
0.96) (218). Similarly, test- retest reliability (intraclass correlation 
coefficients) of the total score of the Finnish VAS- FA was 0.93 
(216).
Validity. Content validity was not examined in the original 
study (213). Criterion validity has not been determined because 
of the absence of a gold standard measure of foot and ankle pain 
and function. Construct validity has been demonstrated by the 
observation of moderate associations (greater than or equal to 
0.4; Spearman’s ρ or Pearson’s r) between the German VAS- FA 
total score and the SF- 36 domain scores: overall, 0.6; pain, 0.5; 
function, 0.6; and other complaints, 0.5 (213). Similarly, associa-
tions of varying magnitude have been shown between the Thai 
VAS- FA total score and SF- 36 domain scores, with stronger rela-
tionships for the physical component summary score (physical 
functioning, 0.55; role physical, 0.60; bodily pain, 0.61; general 
health, 0.37) than the mental component summary score (vitality, 
0.22; social functioning, 0.36; role emotional, 0.35; and mental 
health, 0.18), suggestive of good convergent and divergent validity 
(215). Associations (Pearson’s r) between the Turkish VAS- FA total 
and domain scores and the SF- 36 (total, 0.34- 0.55; pain, 0.03- 
0.52; function, 0.27- 0.32) have been reported in individuals with 
and without foot pain (218). Supporting these findings, the Finn-
ish VAS- FA total and domain scores have been reported to have 
associations (Spearman’s ρ or Pearson’s r) with the total score 
and dimensions of the 15- Dimensional Health- Related Quality of 
Life Questionnaire, particularly the dimensions of mobility, usual 
activities, discomfort and symptoms, and vitality (216,219).
Associations (Pearson’s r) between the Turkish VAS- FA total 
and domain scores with the FFI (total, 0.40- 0.51; pain, 0.47- 0.48; 
function, 0.05- 0.53) and FAOS (total, 0.50- 0.55; pain, 0.47- 0.54; 
function, 0.34- 0.37; other complaints, 0.19- 0.28) have been 
reported for individuals with and without foot pain (218). Sup-
porting these findings, the Finnish VAS- FA total score has been 
reported to have a strong association (Spearman’s ρ) with the 
Lower Extremity Functional Scale (0.86) and the Western Ontario 
and McMaster Universities Osteoarthritis Index total score and 
subscales (0.75- 0.84) (216,219,220).
Responsiveness. Responsiveness of the VAS- FA has not 
been reported.
Minimally important differences. The minimally impor-
tant difference values for the VAS- FA total score or domains have 
not been reported.
Generalizability. The VAS- FA has broad generalizability. It 
was originally developed to be used to evaluate the effectiveness of 
surgical and nonsurgical interventions for foot and ankle disorders 
(213). Its psychometric properties have been evaluated in individ-
uals with a range of osseous (eg, infection, tumors, fractures, and 
osteoarthritis) (216–219) and soft tissue (eg, nonspecific arthritis, 
plantar fasciitis, tarsal tunnel syndrome, tenosynovitis, bursitis, 
and ankle sprains) disorders of the foot and ankle (218).
Use in clinical trials. The VAS- FA has been used in a 
limited number of randomized trials. These trials include the 
evaluation of active controlled movement in individuals after 
surgery for unstable ankle fracture (221), endoscopic versus 
open excision of symptomatic os trigonum for posterior ankle 
impingement syndrome (222), intraoperative pedobarography 
for individuals undergoing foot and/or ankle surgery (223), and 
extracorporeal shockwave therapy for insertional Achilles tendi-
nopathy (224).
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the VAS- FA include its broad 
generalizability, its inclusion of two key distinct domains of foot 
health (pain and function), it being freely available and relatively 
quick to administer and score, its availability in several languages, 
its excellent reliability, and its substantial construct validity.
Caveats and cautions. The VAS- FA was originally 
described by using asymptomatic individuals. Content validity has 
not been evaluated. The VAS- FA is most weighted for the function 
domain (11 items) relative to the other domains of pain and other 
complaints (4 and 5 items, respectively). The responsiveness 
and minimally important difference values have not been reported. 
Finally, a Rasch analysis has not yet been undertaken.
Clinical usability. The VAS- FA is a feasible outcome for 
use in clinical practice. It is simple and quick to administer and 
score. The scoring system accommodates for missing values.
Research usability. Although the VAS- FA has undergone 
substantial psychometric evaluation for its construct validity, its 
content validity, its responsiveness, and the minimally important 
difference values require evaluation.
CONCLUSIONS
This review has outlined the most frequently used patient- 
reported outcome measures that evaluate pain, function, and 
general health for people with foot and ankle conditions. Table 1 
provides a summary of the practical application of each patient- 
reported outcome measure, and Table 2 outlines the psychomet-
ric properties of each patient- reported outcome measure. The 
outcome measures reviewed have undergone varying degrees of 
psychometric validation, and each has advantages and disadvan-
tages. The selection of the most appropriate measure is therefore 
dependent on the context (ie, clinical or research use), the condi-
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tion and population being evaluated, and the usability/accepta-
bility to patients or research participants.
Based on our evaluation of the literature, we recommend 
the use of the FFI- R, FHSQ, or MOXFQ for clinical trials of gen-
eral foot disorders; the FAAM for sports- related ankle conditions; 
the LFIS for inflammatory disorders; and the MOXFQ or SEFAS 
for foot surgery. The MFPDI appears to be better suited to popu-
lation surveys than clinical trials, and both the FAOS and VAS- FA 
require more psychometric development (specifically calculation 
of minimally important difference values and responsiveness and 
a Rasch analysis) before they can be recommended for research 
use. Despite being widely used, the AOFAS advises against 
using the AOFAS scales because of questionable validity and 
reliability.
Further research is required to improve the performance of 
foot and ankle outcome measures in both clinical practice and 
research settings. Specifically, many of these measures lack 
population- based normative data or minimally important differ-
ences, few have undergone Rasch analysis, and few have been 
validated in populations beyond the initial validation studies. 
Addressing these shortcomings will help optimize the assessment 
and management of individuals with musculoskeletal foot disor-
ders.
AUTHOR CONTRIBUTIONS
All authors drafted the article, revised it critically for important 
intellectual content, and approved the final version to be published.
REFERENCES
 1. Thomas MJ, Roddy E, Zhang W, Menz HB, Hannan MT, Peat GM. 
The population prevalence of foot and ankle pain in middle and old 
age: a systematic review. Pain 2011;152:2870–80.
 2. Keenan AM, Drake C, Conaghan PG, Tennant A. The prevalence 
and impact of self- reported foot and ankle pain in the over 55 age 
group: a secondary data analysis from a large community sample. 
J Foot Ankle Res 2019;12:53.
 3. Otter SJ, Lucas K, Springett K, Moore A, Davies K, Cheek L, et al. 
Foot pain in rheumatoid arthritis prevalence, risk factors and man-
agement: an epidemiological study. Clin Rheumatol 2010;29:255–
71.
 4. Carter K, Lahiri M, Cheung PP, Santosa A, Rome K. Prevalence of 
foot problems in people with inflammatory arthritis in Singapore. J 
Foot Ankle Res 2016;9:37.
 5. Hyslop E, McInnes IB, Woodburn J, Turner DE. Foot problems in 
psoriatic arthritis: high burden and low care provision [letter]. Ann 
Rheum Dis 2010;69:928.
 6. Yano K, Ikari K, Inoue E, Sakuma Y, Mochizuki T, Koenuma N, et al. 
Features of patients with rheumatoid arthritis whose debut joint is 
a foot or ankle joint: a 5,479- case study from the IORRA cohort. 
PLoS One 2018;13:e0202427.
 7. Jia Y, Huang H, Gagnier JJ. A systematic review of measurement 
properties of patient- reported outcome measures for use in pa-
tients with foot or ankle diseases. Qual Life Res 2017;26:1969–
2010.
 8. Kitaoka HB, Alexander IJ, Adelaar RS, Nunley JA, Myerson MS, 
Sanders M. Clinical rating systems for the ankle- hindfoot, midfoot, 
hallux, and lesser toes. Foot Ankle Int 1994;15:349–53.
 9. Schneider W, Jurenitsch S. Normative data for the American Ortho-
pedic Foot and Ankle Society ankle- hindfoot, midfoot, hallux and 
lesser toes clinical rating system. Int Orthop 2016;40:301–6.
 10. De Boer AS, Tjioe RJ, van der Sijde F, Meuffels DE, den Hoed PT, 
van der Vlies CH, et al. The American Orthopaedic Foot and Ankle 
Society Ankle- Hindfoot Scale; translation and validation of the Dutch 
language version for ankle fractures. BMJ Open 2017;7:e017040.
 11. Kostuj T, Krummenauer F, Schaper K, Stief F, Zettersten K, Baums 
MH, et al. Analysis of agreement between the German transla-
tion of the American Foot and Ankle Society’s Ankle and Hindfoot 
Scale (AOFAS- AHS) and the Foot Function Index in its validated 
German translation by Naal et al. (FFI- D). Arch Orthop Traum Surg 
2014;134:1205–10.
 12. Leigheb M, Janicka P, Andorno S, Marcuzzi A, Magnani C, Grassi 
F. Italian translation, cultural adaptation and validation of the “Amer-
ican Orthopaedic Foot and Ankle Society’s (AOFAS) ankle- hindfoot 
scale.” Acta Biomed 2016;87:38–45.
 13. Vosoughi AR, Roustaei N, Mahdaviazad H. American Orthopaedic 
Foot and Ankle Society ankle- hindfoot scale: a cross- cultural ad-
aptation and validation study from Iran. Foot Ankle Surg 2018;24: 
219–23.
 14. Sayyed-Hosseinian SH, Hassankhani GG, Bagheri F, Alavi N, 
Shojaie B, Mousavian A. Validation of the Persian version of the 
American Orthopedic Foot and Ankle Society Score (AOFAS) ques-
tionnaire. Arch Bone Jt Surg 2018;6:233–9.
 15. Rodrigues RC, Masiero D, Mizusaki JM, Imoto AM, Peccin MS, 
Cohen M, et al. Translation, cultural adaptation and validity of the 
“American Orthopaedic Foot and Ankle Society (AOFAS) Ankle- 
Hindfoot Scale.” Acta Ortop Bras 2008;16:107–11.
 16. Analay Akbaba Y, Celik D, Ogut RT. Translation, cross- cultural ad-
aptation, reliability, and validity of Turkish version of the American 
Orthopaedic Foot and Ankle Society Ankle- Hindfoot Scale. J Foot 
Ankle Surg 2016;55:1139–42.
 17. Da Cunha RA, Hazime FA, da Silva Martins MC, Ferreira M, de Castro 
Pochini A, Ejnisman B. Translation, cross- cultural adaptation, and 
clinimetric testing of instruments used to assess patients with an-
kle sprain in the Brazilian population. J Orthop Sports Phys Ther 
2016;46:1042–50.
 18. SooHoo NF, Shuler M, Fleming LL, American Orthopaedic Foot 
and Ankle Society. Evaluation of the validity of the AOFAS Clin-
ical Rating Systems by correlation to the SF- 36. Foot Ankle Int 
2003;24:50–5.
 19. Cöster MC, Rosengren BE, Bremander A, Brudin L, Karlsson MK. 
Comparison of the Self- Reported Foot and Ankle Score (SEFAS) 
and the American Orthopedic Foot and Ankle Society Score (AO-
FAS). Foot Ankle Int 2014;35:1031–6.
 20. Ponkilainen VT, Uimonen M, Repo JP, Mattila VM, Haapasalo HH. 
Validity and internal consistency of the American Orthopaedic Foot 
and Ankle Society Midfoot Scale in patients with Lisfranc injury. 
Foot Ankle Surg 2019;S1268-7731:30101-8.
 21. Baumhauer JF, Nawoczenski DA, DiGiovanni BF, Wilding GE. Re-
liability and validity of the American Orthopaedic Foot and Ankle 
Society Clinical Rating Scale: a pilot study for the hallux and lesser 
toes. Foot Ankle Int 2006;27:1014–9.
 22. Pinsker E, Daniels TR. AOFAS position statement regarding 
the future of the AOFAS Clinical Rating Systems. Foot Ankle Int 
2011;32:841–2.
 23. SooHoo NF, Vyas R, Samini D. Responsiveness of the foot function 
index, AOFAS clinical rating systems, and SF- 36 after foot and an-
kle surgery. Foot Ankle Int 2006;27:930–4.
 24. Madeley NJ, Wing KJ, Topliss C, Penner MJ, Glazebrook MA, 
Younger AS. Responsiveness and validity of the SF- 36, Ankle Os-
teoarthritis Scale, AOFAS Ankle Hindfoot Score, and Foot Function 
Index in end stage ankle arthritis. Foot Ankle Int 2012;33:57–63.
WHITTAKER ET AL 312       |
 25. Dawson J, Doll H, Coffey J, Jenkinson C, Oxford and Birmingham 
Foot and Ankle Clinical Research Group. Responsiveness and mini-
mally important change for the Manchester- Oxford Foot Questionnaire 
(MOXFQ) compared with AOFAS and SF- 36 assessments following 
surgery for hallux valgus [published erratum appears in Osteoarthritis 
Cartilage 2011;19:920]. Osteoarthritis Cartilage 2007;15:918–31.
 26. Chan HY, Chen JY, Zainul-Abidin S, Ying H, Koo K, Rikhraj IS. 
Minimal clinically important differences for American Orthopaedic 
Foot & Ankle Society score in hallux valgus surgery. Foot Ankle Int 
2017;38:551–7.
 27. Naal FD, Impellizzeri FM, Rippstein PF. Which are the most fre-
quently used outcome instruments in studies on total ankle arthro-
plasty? [review]. Clin Orthop Relat Res 2010;468:815–26.
 28. Lau JT, Mahomed NM, Schon LC. Results of an Internet survey de-
termining the most frequently used ankle scores by AOFAS mem-
bers. Foot Ankle Int 2005;26:479–82.
 29. Hijji FY, Schneider AD, Pyper M, Laughlin RT. The popularity of out-
come measures used in the foot and ankle literature. Foot Ankle 
Spec 2020;13:58–68.
 30. Schrier JC, Keijsers NL, Matricali GA, Verheyen CC, Louwerens 
JW. Resection or preservation of the metatarsal heads in rheuma-
toid forefoot surgery? A randomised clinical trial. Foot Ankle Surg 
2019;25:37–46.
 31. DeGroot H III, Uzunishvili S, Weir R, Al-omari A, Gomes B. Intra- 
articular injection of hyaluronic acid is not superior to saline solution 
injection for ankle arthritis: a randomized, double- blind, placebo- 
controlled study. J Bone Joint Surg Am 2012;94:2–8.
 32. Sultan MJ, McKeown A, McLaughlin I, Kurdy N, McCollum CN. 
Elastic stockings or Tubigrip for ankle sprain: a randomised clinical 
trial. Injury 2012;43:1079–83.
 33. Guo JJ, Tang N, Yang HL, Tang TS. A prospective, randomised trial 
comparing closed intramedullary nailing with percutaneous plating 
in the treatment of distal metaphyseal fractures of the tibia [pub-
lished erratum appears in J Bone Joint Surg Br 2010;92:1717]. J 
Bone Joint Surg Br 2010;92:984–8.
 34. Boyle MJ, Gao R, Frampton CM, Coleman B. Removal of the syn-
desmotic screw after the surgical treatment of a fracture of the 
ankle in adult patients does not affect one- year outcomes: a ran-
domised controlled trial. Bone Joint J 2014;96-B:1699–705.
 35. Khurana A, Dhillon MS, Prabhakar S, John R. Outcome evaluation 
of minimally invasive surgery versus extensile lateral approach in 
management of displaced intra- articular calcaneal fractures: a ran-
domised control trial. Foot (Edinb) 2017;31:23–30.
 36. Ly TV, Coetzee JC. Treatment of primarily ligamentous Lisfranc joint 
injuries: primary arthrodesis compared with open reduction and in-
ternal fixation: a prospective, randomized study. J Bone Joint Surg 
Am 2006;88:514–20.
 37. Zenios M, Kim WY, Sampath J, Muddu BN. Functional treatment of 
acute metatarsal fractures: a prospective randomised comparison 
of management in a cast versus elasticated support bandage. Inju-
ry 2005;36:832–5.
 38. Rasmussen S, Christensen M, Mathiesen I, Simonson O. Shock-
wave therapy for chronic Achilles tendinopathy: a double- blind, 
randomized clinical trial of efficacy. Acta Orthop 2008;79:249–56.
 39. Jain SK, Suprashant K, Kumar S, Yadav A, Kearns SR. Compari-
son of plantar fasciitis injected with platelet- rich plasma vs corticos-
teroids. Foot Ankle Int 2018;39:780–6.
 40. Jeuken RM, Schotanus MG, Kort NP, Deenik A, Jong B, Hendrickx 
RP. Long- term follow- up of a randomized controlled trial comparing 
scarf to chevron osteotomy in hallux valgus correction. Foot Ankle 
Int 2016;37:687–95.
 41. Saro C, Andren B, Wildemyr Z, Fellander-Tsai L. Outcome af-
ter distal metatarsal osteotomy for hallux valgus: a prospec-
tive randomized controlled trial of two methods. Foot Ankle Int 
2007;28:778–87.
 42. Lee KB, Cho NY, Park HW, Seon JK, Lee SH. A comparison of 
proximal and distal chevron osteotomy, both with lateral soft- tissue 
release, for moderate to severe hallux valgus in patients undergoing 
simultaneous bilateral correction: a prospective randomised con-
trolled trial. Bone Joint J 2015;97-B:202–7.
 43. Faber FW, Mulder PG, Verhaar JA. Role of first ray hypermobility in 
the outcome of the Hohmann and the Lapidus procedure: a pro-
spective, randomized trial involving one hundred and one feet. J 
Bone Joint Surg Am 2004;86:486–95.
 44. Guyton GP. Theoretical limitations of the AOFAS scoring sys-
tems: an analysis using Monte Carlo modeling. Foot Ankle Int 
2001;22:779–87.
 45. Martin RL, Irrgang JJ, Burdett RG, Conti SF, Swearingen JM. Ev-
idence of validity for the Foot and Ankle Ability Measure (FAAM). 
Foot Ankle Int 2005;26:968–83.
 46. Matheny L, Clanton T, Gittner K, Harding J. Normative values for 
commonly reported outcome measures in the foot and ankle [ab-
stract]. Foot Ankle Orthop 2018;3. URL: https://journ als.sagep 
ub.com/doi/abs/10.1177/24730 11418 S00011
 47. Moreira TS, Magalhaes Lde C, Silva RD, Martin RL, Resende MA. 
Translation, cross- cultural adaptation and validity of the Brazilian 
version of the Foot and Ankle Ability Measure questionnaire. Disabil 
Rehabil 2016;38:2479–90.
 48. Gonzalez-Sanchez M, Li GZ, Ruiz Munoz M, Cuesta-Vargas AI. 
Foot and ankle ability measure to measure functional limitations 
in patients with foot and ankle disorders: a Chinese cross- cultural 
adaptation and validation. Disabil Rehabil 2017;39:2182–9.
 49. Nauck T, Lohrer H. Translation, cross- cultural adaption and vali-
dation of the German version of the Foot and Ankle Ability Meas-
ure for patients with chronic ankle instability. Br J Sports Med 
2011;45:785–90.
 50. Sartorio F, Vercelli S, Bravini E, Bargeri S, Moroso M, Plebani G, 
et al. Foot and ankle ability measure: cross- cultural translation and 
validation of the Italian version of the ADL module (FAAM- I/ADL). 
Med Lav 2014;105:357–65. In Italian.
 51. Uematsu D, Suzuki H, Sasaki S, Nagano Y, Shinozuka N, Sunaga-
wa N, et al. Evidence of validity for the Japanese version of the Foot 
and Ankle Ability Measure. J Athl Train 2015;50:65–70.
 52. Cervera-Garvi P, Ortega-Avila AB, Morales-Asencio JM, Cerve-
ra-Marin JA, Martin RR, Gijon-Nogueron G. Cross- cultural adapta-
tion and validation of Spanish version of the Foot and Ankle Ability 
Measures (FAAM- Sp). J Foot Ankle Res 2017;10:39.
 53. Celik D, Malkoc M, Martin R. Evidence for reliability, validity and 
responsiveness of Turkish Foot and Ankle Ability Measure (FAAM). 
Rheumatol Int 2016;36:1469–76.
 54. Weel H, Zwiers R, Azim D, Sierevelt IN, Haverkamp D, van Dijk 
CN, et al. Validity and reliability of a Dutch version of the Foot 
and Ankle Ability Measure. Knee Surg Sports Traumatol Arthrosc 
2016;24:1348–54.
 55. Borloz S, Crevoisier X, Deriaz O, Ballabeni P, Martin RL, Luthi F. 
Evidence for validity and reliability of a French version of the FAAM. 
BMC Musculoskelet Disord 2011;12:40.
 56. Mazaheri M, Salavati M, Negahban H, Sohani S, Taghizadeh F, 
Feizi A, et al. Reliability and validity of the Persian version of Foot 
and Ankle Ability Measure (FAAM) to measure functional limitations 
in patients with foot and ankle disorders. Osteoarthritis Cartilage 
2010;18:755–9.
 57. Arunakul M, Arunakul P, Suesiritumrong C, Angthong C, Chern-
chujit B. Validity and reliability of Thai version of the Foot and An-
kle Ability Measure (FAAM) subjective form. J Med Assoc Thai 
2015;98:561–7.
MEASURES OF FOOT PAIN, FUNCTION, AND GENERAL HEALTH |      313
 58. Kivlan BR, Martin RL, Wukich DK. Responsiveness of the Foot and 
Ankle Ability Measure (FAAM) in individuals with diabetes. Foot (Ed-
inb) 2011;21:84–7.
 59. Matheny LM, Clanton TO. Rasch analysis of reliability and validity of 
scores from the Foot and Ankle Ability Measure (FAAM). Foot Ankle 
Int 2020;41:229–36.
 60. Nixon DC, McCormick JJ, Johnson JE, Klein SE. PROMIS pain 
interference and physical function scores correlate with the Foot 
And Ankle Ability Measure (FAAM) in patients with hallux valgus. 
Clin Orthop Relat Res 2017;475:2775–80.
 61. Hung M, Baumhauer JF, Licari FW, Voss MW, Bounsanga J, 
Saltzman CL. PROMIS and FAAM minimal clinically impor-
tant differences in foot and ankle orthopedics. Foot Ankle Int 
2019;40:65–73.
 62. Gonzalez de Vega C, Speed C, Wolfarth B, Gonzalez J. Traumeel 
vs. diclofenac for reducing pain and improving ankle mobility after 
acute ankle sprain: a multicentre, randomised, blinded, controlled 
and non- inferiority trial. Int J Clin Pract 2013;67:979–89.
 63. Wainwright TW, Burgess LC, Middleton RG. Does neuromuscu-
lar electrical stimulation improve recovery following acute ankle 
sprain? A pilot randomised controlled trial. Clin Med Insights Arthri-
tis Musculoskelet Disord 2019;12:1179544119849024.
 64. Cruz-Diaz D, Lomas-Vega R, Osuna-Pérez MC, Contreras FH, 
Martínez-Amat A. Effects of 6 weeks of balance training on chron-
ic ankle instability in athletes: a randomized controlled trial. Int J 
Sports Med 2015;36:754–60.
 65. Celik D, Kuş G, Sırma SÖ. Joint mobilization and stretching exer-
cise vs steroid injection in the treatment of plantar fasciitis: a rand-
omized controlled study. Foot Ankle Int 2016;37:150–6.
 66. Cleland JA, Abbott JH, Kidd MO, Stockwell S, Cheney S, Gerrard 
DF, et al. Manual physical therapy and exercise versus electrophys-
ical agents and exercise in the management of plantar heel pain: 
a multicenter randomized clinical trial. J Orthop Sports Phys Ther 
2009;39:573–85.
 67. Wheeler PC. The addition of a tension night splint to a structured 
home rehabilitation programme in patients with chronic plantar fas-
ciitis does not lead to significant additional benefits in either pain, 
function or flexibility: a single- blinded randomised controlled trial. 
BMJ Open Sport Exerc Med 2017;3:e000234.
 68. Babaei-Ghazani A, Karimi N, Forogh B, Madani SP, Ebadi S, 
Fadavi HR, et al. Comparison of ultrasound- guided local ozone 
(O2- O3) injection vs corticosteroid injection in the treatment of 
chronic plantar fasciitis: a randomized clinical trial. Pain Med 
2019;20:314–22.
 69. Franettovich Smith MM, Coates SS, Creaby MW. A comparison 
of rigid tape and exercise, elastic tape and exercise and exercise 
alone on pain and lower limb function in individuals with exercise 
related leg pain: a randomised controlled trial. BMC Musculoskelet 
Disord 2014;15:328.
 70. Rohner-Spengler M, Frotzler A, Honigmann P, Babst R. Effective 
treatment of posttraumatic and postoperative edema in patients 
with ankle and hindfoot fractures: a randomized controlled trial 
comparing multilayer compression therapy and intermittent impulse 
compression with the standard treatment with ice. J Bone Joint 
Surg Am 2014;96:1263–71.
 71. Martin RL, Davenport TE, Reischl SF, McPoil TG, Matheson JW, 
Wukich DK, et al. Heel pain- plantar fasciitis: revision 2014. J Orthop 
Sports Phys Ther 2014;44:A1–33.
 72. Delahunt E, Bleakley CM, Bossard DS, Caulfield BM, Docherty 
CL, Doherty C, et al. Clinical assessment of acute lateral ankle 
sprain injuries (ROAST): 2019 consensus statement and recom-
mendations of the International Ankle Consortium. Br J Sports Med 
2018;52:1304–10.
 73. Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD. Knee 
Injury and Osteoarthritis Outcome Score (KOOS): development of 
a self- administered outcome measure. J Orthop Sports Phys Ther 
1998;28:88–96.
 74. Roos EM, Brandsson S, Karlsson J. Validation of the foot and ankle 
outcome score for ankle ligament reconstruction. Foot Ankle Int 
2001;22:788–94.
 75. Ling SK, Chan V, Ho K, Ling F, Lui TH. Reliability and validity anal-
ysis of the open- source Chinese Foot and Ankle Outcome Score 
(FAOS). Foot (Edinb) 2018;35:48–51.
 76. Larsen P, Boe AM, Iyer AB, Elsoe R. Danish translation of the Foot 
and Ankle Outcome Score. Dan Med J 2017;64:A5427.
 77. Sierevelt IN, Beimers L, van Bergen CJ, Haverkamp D, Terwee CB, 
Kerkhoffs GM. Validation of the Dutch language version of the Foot 
and Ankle Outcome Score. Knee Surg Sports Traumatol Arthrosc 
2015;23:2413–9.
 78. Van Bergen CJ, Sierevelt IN, Hoogervorst P, Waizy H, van Dijk 
CN, Becher C. Translation and validation of the German version 
of the Foot and Ankle Outcome Score. Arch Orthop Traum Surg 
2014;134:897–901.
 79. Lee KM, Chung CY, Kwon SS, Sung KH, Lee SY, Won SH, et al. 
Transcultural adaptation and testing psychometric properties of the 
Korean version of the Foot and Ankle Outcome Score (FAOS). Clin 
Rheumatol 2013;32:1443–50.
 80. Negahban H, Mazaheri M, Salavati M, Sohani SM, Askari M, Fanian 
H, et al. Reliability and validity of the Foot and Ankle Outcome Score: 
a validation study from Iran. Clin Rheumatol 2010;29:479–86.
 81. Angthong C. Validity and reliability of Thai version of the Foot and 
Ankle Outcome Score in patients with arthritis of the foot and ankle. 
Foot Ankle Surg 2016;22:224–8.
 82. Karatepe AG, Gunaydin R, Kaya T, Karlibas U, Ozbek G. Validation 
of the Turkish version of the Foot and Ankle Outcome Score. Rheu-
matol Int 2009;30:169–73.
 83. Mani SB, Do H, Vulcano E, Hogan MV, Lyman S, Deland JT, et al. 
Evaluation of the Foot and Ankle Outcome Score in patients with 
osteoarthritis of the ankle. Bone Joint J 2015;97-B:662–7.
 84. Golightly YM, Devellis RF, Nelson AE, Hannan MT, Lohmander LS, 
Renner JB, et al. Psychometric properties of the Foot and Ankle Out-
come Score in a community- based study of adults with and without 
osteoarthritis. Arthritis Care Res (Hoboken) 2014;66:395–403.
 85. Chen L, Lyman S, Do H, Karlsson J, Adam SP, Young E, et al. 
Validation of Foot and Ankle Outcome Score for hallux valgus. Foot 
Ankle Int 2012;33:1145–55.
 86. Mani SB, Brown HC, Nair P, Chen L, Do HT, Lyman S, et al. Valida-
tion of the Foot and Ankle Outcome Score in adult acquired flatfoot 
deformity. Foot Ankle Int 2013;34:1140–6.
 87. Sierevelt IN, van Eekeren IC, Haverkamp D, Reilingh ML, Terwee 
CB, Kerkhoffs GM. Evaluation of the Dutch version of the Foot 
and Ankle Outcome Score (FAOS): responsiveness and mini-
mally important change. Knee Surg Sports Traumatol Arthrosc 
2016;24:1339–47.
 88. Brison RJ, Day AG, Pelland L, Pickett W, Johnson AP, Aiken A, et al. 
Effect of early supervised physiotherapy on recovery from acute an-
kle sprain: randomised controlled trial. BMJ 2016;355:i5650.
 89. Cooke MW, Marsh JL, Clark M, Nakash R, Jarvis RM, Hutton JL, 
et al. Treatment of severe ankle sprain: a pragmatic randomised 
controlled trial comparing the clinical effectiveness and cost- 
effectiveness of three types of mechanical ankle support with tu-
bular bandage. The CAST trial. Health Technol Assess 2009;13:iii, 
ix-x, 1–121.
 90. Best R, Bohle C, Schiffer T, Petersen W, Ellermann A, Bruegge-
mann GP, et al. Early functional outcome of two different orthotic 
WHITTAKER ET AL 314       |
concepts in ankle sprains: a randomized controlled trial. Arch Or-
thop Traum Surg 2015;135:993–1001.
 91. Porter M, Shadbolt B, Ye X, Stuart R. Ankle lateral ligament 
augmentation versus the modified Brostrom- Gould proce-
dure: a 5- year randomized controlled trial. Am J Sports Med 
2019;47:659–66.
 92. Cho BK, Park JK, Choi SM, SooHoo NF. A randomized compari-
son between lateral ligaments augmentation using suture- tape and 
modified Broström repair in young female patients with chronic an-
kle instability. Foot Ankle Surg 2019;25:137–42.
 93. Porter M, Shadbolt B, Stuart R. Primary ankle ligament augmen-
tation versus modified Brostrom- Gould procedure: a 2- year rand-
omized controlled trial. ANZ J Surg 2015;85:44–8.
 94. Mardh A, Lund I. High power laser for treatment of achilles tendi-
nosis: a single blind randomized placebo controlled clinical study. J 
Lasers Med Sci 2016;7:92–8.
 95. Knobloch K, Schreibmueller L, Longo UG, Vogt PM. Eccentric ex-
ercises for the management of tendinopathy of the main body of 
the Achilles tendon with or without the AirHeel Brace: a randomized 
controlled trial. A. Effects on pain and microcirculation. Disabil Re-
habil 2008;30:1685–91.
 96. Tennant A, Conaghan PG. The Rasch measurement model in rheu-
matology: what is it and why use it? When should it be applied, and 
what should one look for in a Rasch paper? [special article]. Arthritis 
Rheum 2007;57:1358–62.
 97. Park JY, Kim BS, Lee HJ, Kim YM, Kim HN, Kang HJ, et al. Compar-
ison between an electronic version of the Foot and Ankle Outcome 
Score and the standard paper version: a randomized multicenter 
study. Medicine (Baltimore) 2019;98:e17440.
 98. Sierevelt IN, Zwiers R, Schats W, Haverkamp D, Terwee CB, 
Nolte PA, et al. Measurement properties of the most commonly 
used foot- and ankle- specific questionnaires: the FFI, FAOS and 
FAAM: a systematic review. Knee Surg Sports Traumatol Arthrosc 
2018;26:2059–73.
 99. Budiman-Mak E, Conrad KJ, Roach KE. The foot function index: a 
measure of foot pain and disability. J Clin Epidemiol 1991;44:561–70.
 100. Budiman-Mak E, Conrad K, Stuck R, Matters M. Theoretical model 
and Rasch analysis to develop a revised Foot Function Index. Foot 
Ankle Int 2006;27:519–27.
 101. Budiman-Mak E, Conrad KJ, Mazza J, Stuck RM. A review of the 
Foot Function Index and the Foot Function Index – Revised. J Foot 
Ankle Res 2013;6:5.
 102. Schneider W, Jurenitsch S. Age- and sex- related normative data for 
the Foot Function Index in a German- speaking cohort. Foot Ankle 
Int 2016;37:1238–42.
 103. Stefani KC, Pereira MV, Oliveira PR, Wun PY. Translation, cultur-
al adaptation and validation of the Foot Function Index - Revised 
(FFI- R). Acta Ortop Bras 2017;25:188–93.
 104. Rutkowski R, Gałczyńska-Rusin M, Gizińska M, Straburzyński-Lu-
pa M, Zdanowska A, Romanowski MW, et al. Adaptation and val-
idation of the Foot Function Index- Revised short form into Polish. 
Biomed Res Int 2017;2017:6051698.
 105. Yagci G, Erel S, Okunakol V. Validation of the Turkish version of the 
Revised Foot Function Index for patients with foot and ankle disor-
ders. Foot Ankle Surg 2019;S1268-7731:30134-1.
 106. Menz HB, Auhl M, Tan JM, Levinger P, Roddy E, Munteanu 
SE. Comparative responsiveness of outcome measures for 
the assessment of pain and function in osteoarthritis of the 
first metatarsophalangeal joint. Arthritis Care Res (Hoboken) 
2020;72:679–84.
 107. Rao S, Baumhauer JF, Tome J, Nawoczenski DA. Orthoses alter 
in vivo segmental foot kinematics during walking in patients with 
midfoot arthritis. Arch Phys Med Rehabil 2010;91:608–14.
 108. Dux K, Smith N, Rottier FJ. Outcome after metatarsal osteoto-
my for hallux valgus: a study of postoperative foot function us-
ing revised Foot Function Index short form. J Foot Ankle Surg 
2013;52:422–5.
 109. Myerson CL, Myerson MS, Coetzee JC, Stone McGaver R, 
Giveans MR. Subtalar arthrodesis with use of adipose- derived 
cellular bone matrix compared with autologous bone graft: a 
multicenter, randomized controlled trial. J Bone Joint Surg Am 
2019;101:1904–11.
 110. Hunt MA, Takacs J, Krowchuk NM, Hatfield GL, Hinman RS, Chang 
R. Lateral wedges with and without custom arch support for people 
with medial knee osteoarthritis and pronated feet: an exploratory 
randomized crossover study. J Foot Ankle Res 2017;10:20.
 111. Menz HB, Auhl M, Tan JM, Levinger P, Roddy E, Munteanu SE. 
Effectiveness of foot orthoses versus rocker- sole footwear for first 
metatarsophalangeal joint osteoarthritis: randomized trial [published 
erratum appears in Arthritis Care Res (Hoboken) 2018;70:1420]. 
Arthritis Care Res (Hoboken) 2016;68:581–9.
 112. Cazzell S, Stewart J, Agnew PS, Senatore J, Walters J, Murdoch 
D, et al. Randomized controlled trial of micronized dehydrated 
human amnion/chorion membrane (dHACM) injection compared 
to placebo for the treatment of plantar fasciitis. Foot Ankle Int 
2018;39:1151–61.
 113. Uğurlar M, Sönmez MM, Uğurlar ÖY, Adıyeke L, Yıldırım H, Eren 
OT. Effectiveness of four different treatment modalities in the 
treatment of chronic plantar fasciitis during a 36- month follow- 
up period: a randomized controlled trial. J Foot Ankle Surg 
2018;57:913–8.
 114. Uğurlar M, Sönmez MM, Armağan R, Eren OT. Comparison of 
two different vacuum- assisted closure (VAC) treatments of multi-
ple chronic diabetic foot wounds in the same extremity. Foot Ankle 
Surg 2017;23:173–8.
 115. Bennett PJ, Patterson C, Wearing S, Baglioni T. Development and 
validation of a questionnaire designed to measure foot- health sta-
tus. J Am Podiatr Med Assoc 1998;88:419–28.
 116. Bennett PJ, Patterson C. The Foot Health Status Questionnaire 
(FHSQ): a new instrument for measuring outcomes of footcare. 
Australas J Podiatr Med 1998;32:87–92.
 117. Ferreira AF, Laurindo IM, Rodrigues PT, Ferraz MB, Kowalski SC, 
Tanaka C. Brazilian version of the Foot Health Status Questionnaire 
(FHSQ- BR): cross- cultural adaptation and evaluation of measure-
ment properties. Clinics (Sao Paulo) 2008;63:595–600.
 118. Riel H, Jensen MB, Olesen JL, Rathleff MS. Translation and cul-
tural adaptation of a Danish version of the Foot Health Status 
Questionnaire for individuals with plantar heel pain. Foot (Edinb) 
2019;38:61–4.
 119. Berger L, Bry C, Calleja J, Maligorne M, Avenaz K, Blanc C. Vali-
dation of foot function and pain questionnaire in French language 
[abstract]. Ann Phys Rehabil Med 2012;55 Suppl 1:e59.
 120. Cuesta-Vargas A, Bennett P, Jimenez-Cebrian AM, Labajos-Man-
zanares MT. The psychometric properties of the Spanish version 
of the Foot Health Status Questionnaire. Qual Life Res 2013;22: 
1739–43.
 121. Sirera-Vercher MJ, Sáez-Zamora P, Sanz-Amaro MD. Translation, 
transcultural adaptation to Spanish, to Valencian language of the 
Foot Health Status Questionnaire. Rev Esp Cir Ortop Traumatol 
2010;54:211–9.
 122. Keysor JJ, Dunn JE, Link CL, Badlissi F, Felson DT. Are foot dis-
orders associated with functional limitation and disability among 
community- dwelling older adults? [original research]. J Aging 
Health 2005;17:734–52.
 123. Menz HB, Auhl M, Ristevski S, Frescos N, Munteanu SE. Compar-
ison of the responsiveness of the Foot Health Status Questionnaire 
MEASURES OF FOOT PAIN, FUNCTION, AND GENERAL HEALTH |      315
and the Manchester Foot Pain and Disability Index in older people. 
Health Qual Life Outcomes 2014;12:158.
 124. Landorf KB, Radford JA, Hudson S. Minimal important difference 
(MID) of two commonly used outcome measures for foot problems. 
J Foot Ankle Res 2010;3:7.
 125. Chuter VH, Searle A, Spink MJ. Flip- flop footwear with a moulded 
foot- bed for the treatment of foot pain: a randomised controlled 
trial. BMC Musculoskelet Disord 2016;17:468.
 126. Landorf KB, Keenan AM, Herbert RD. Effectiveness of foot or-
thoses to treat plantar fasciitis: a randomized trial. Arch Intern Med 
2006;166:1305–10.
 127. McMillan AM, Landorf KB, Gilheany MF, Bird AR, Morrow AD, Menz 
HB. Ultrasound guided corticosteroid injection for plantar fasciitis: 
randomised controlled trial. BMJ 2012;344:e3260.
 128. Whittaker GA, Munteanu SE, Menz HB, Gerrard JM, Elzarka A, 
Landorf KB. Effectiveness of foot orthoses versus corticosteroid in-
jection for plantar heel pain: the SOOTHE randomized clinical trial. 
J Orthop Sports Phys Ther 2019;49:491–500.
 129. Riel H, Jensen MB, Olesen JL, Vicenzino B, Rathleff MS. Self- 
dosed and pre- determined progressive heavy- slow resistance 
training have similar effects in people with plantar fasciopathy: a 
randomised trial. J Physiother 2019;65:144–51.
 130. Cotchett MP, Munteanu SE, Landorf KB. Effectiveness of trigger 
point dry needling for plantar heel pain: a randomized controlled 
trial. Phys Ther 2014;94:1083–94.
 131. Ye L, Mei Q, Li M, Gu M, Ai Z, Tang K, et al. A comparative efficacy 
evaluation of ultrasound- guided pulsed radiofrequency treatment 
in the gastrocnemius in managing plantar heel pain: a randomized 
and controlled trial. Pain Med 2015;16:782–90.
 132. Munteanu SE, Zammit GV, Menz HB, Landorf KB, Handley CJ, 
Elzarka A, et al. Effectiveness of intra- articular hyaluronan (Synvisc, 
hylan G- F 20) for the treatment of first metatarsophalangeal joint 
osteoarthritis: a randomised placebo- controlled trial. Ann Rheum 
Dis 2011;70:1838–41.
 133. De Oliveira HA, Natour J, Vassalli M, Rosenfeld A, Jennings F, 
Jones A. Effectiveness of customized insoles in patients with Mor-
ton’s neuroma: a randomized, controlled, double- blind clinical trial. 
Clin Rehabil 2019;33:1898–907.
 134. Burns J, Crosbie J, Ouvrier R, Hunt A. Effective orthotic therapy for 
the painful cavus foot: a randomized controlled trial. J Am Podiatr 
Med Assoc 2006;96:205–11.
 135. Williams AE, Rome K, Nester CJ. A clinical trial of specialist foot-
wear for patients with rheumatoid arthritis. Rheumatology (Oxford) 
2007;46:302–7.
 136. Trevethan R. Evaluation of two self- referent foot health instruments. 
Foot (Edinb) 2010;20:101–8.
 137. Maher AJ, Metcalfe SA. A report of UK experience in 917 cases of 
day care foot surgery using a validated outcome tool. Foot (Edinb) 
2009;19:101–6.
 138. Spruce MC, Bowling FL, Metcalfe SA. A longitudinal study of hallux 
valgus surgical outcomes using a validated patient centred out-
come measure. Foot (Edinb) 2011;21:133–7.
 139. Alvey J, Palmer S, Otter S. A comparison of the readability of two 
patient- reported outcome measures used to evaluate foot surgery. 
J Foot Ankle Surg 2012;51:412–4.
 140. Helliwell P, Reay N, Gilworth G, Redmond A, Slade A, Tennant A, 
et al. Development of a foot impact scale for rheumatoid arthritis. 
Arthritis Rheum 2005;53:418–22.
 141. Woodburn J, Turner DE, Rosenbaum D, Balint G, Korda J, Ormos 
G, et al. Adaptation and crosscultural validation of the Foot Impact 
Scale for rheumatoid arthritis using Rasch analysis. Arthritis Care 
Res (Hoboken) 2012;64:986–92.
 142. Turner DE, Helliwell PS, Emery P, Woodburn J. The impact of rheu-
matoid arthritis on foot function in the early stages of disease: a 
clinical case series. BMC Musculoskelet Disord 2006;7:102.
 143. Woodburn J, Vliet Vlieland TP, van der Leeden M, Steultjens 
MP. Rasch analysis of Dutch- translated version of the Foot 
Impact Scale for rheumatoid arthritis. Rheumatology (Oxford) 
2011;50:1315–9.
 144. Muradin I, van der Heide HJ. The Foot Function Index is more sen-
sitive to change than the Leeds Foot Impact Scale for evaluating 
rheumatoid arthritis patients after forefoot or hindfoot reconstruc-
tion. Int Orthop 2016;40:745–9.
 145. Wilkins RA, Siddle HJ, Redmond AC, Helliwell PS. Plantar fore-
foot pressures in psoriatic arthritis- related dactylitis: an exploratory 
study. Clin Rheumatol 2016;35:2333–8.
 146. Rome K, Stewart S, Vandal AC, Gow P, McNair P, Dalbeth N. The 
effects of commercially available footwear on foot pain and disa-
bility in people with gout: a pilot study. BMC Musculoskelet Disord 
2013;14:278.
 147. Rome K, Frecklington M, McNair P, Gow P, Dalbeth N. Foot pain, 
impairment, and disability in patients with acute gout flares: a 
prospective observational study. Arthritis Care Res (Hoboken) 
2012;64:384–8.
 148. Rome K, Frecklington M, Mcnair P, Gow P, Dalbeth N. Footwear 
characteristics and factors influencing footwear choice in patients 
with gout. Arthritis Care Res (Hoboken) 2011;63:1599–604.
 149. Rome K, Erikson K, Otene C, Sahid H, Sangster K, Gow P. Clinical 
characteristics of foot ulceration in people with chronic gout. Int 
Wound J 2016;13:209–15.
 150. Mukherjee S, Cherry L, Zarroug J, Culliford D, Bowen C, Arden 
N, et al. A pilot investigation of the prevalence of US- detectable 
forefoot joint pathology and reported foot- related disability in par-
ticipants with systemic lupus erythematosus. J Foot Ankle Res 
2016;9:27.
 151. Turner DE, Helliwell PS, Woodburn J. Methodological considera-
tions for a randomised controlled trial of podiatry care in rheumatoid 
arthritis: lessons from an exploratory trial. BMC Musculoskelet Dis-
ord 2007;8:109.
 152. Gallagher KS, Godwin J, Hendry GJ, Steultjens M, Woodburn J. 
A protocol for a randomised controlled trial of prefabricated ver-
sus customised foot orthoses for people with rheumatoid arthritis: 
the FOCOS RA trial [Foot Orthoses - Customised v Off- the- Shelf in 
Rheumatoid Arthritis]. J Foot Ankle Res 2018;11:24.
 153. Frecklington M, Dalbeth N, McNair P, Morpeth T, Vandal AC, Gow 
P, et al. Effects of a footwear intervention on foot pain and disability 
in people with gout: a randomised controlled trial. Arthritis Res Ther 
2019;21:104.
 154. Garrow AP, Papageorgiou AC, Silman AJ, Thomas E, Jayson MI, 
Macfarlane GJ. Development and validation of a questionnaire to 
assess disabling foot pain. Pain 2000;85:107–13.
 155. Menz HB, Tiedemann A, Kwan MM, Plumb K, Lord SR. Foot pain 
in community- dwelling older people: an evaluation of the Manches-
ter Foot Pain and Disability Index [published erratum appears in 
Rheumatology (Oxford) 2007;46:375]. Rheumatology (Oxford) 
2006;45:863–7.
 156. Cook CE, Cleland J, Pietrobon R, Garrow AP, Macfarlane GJ. 
Calibration of an item pool for assessing the disability associ-
ated with foot pain: an application of item response theory to 
the Manchester Foot Pain and Disability Index. Physiotherapy 
2007;93:89–95.
 157. Roddy E, Muller S, Thomas E. Defining disabling foot pain in older 
adults: further examination of the Manchester Foot Pain and Disa-
bility Index. Rheumatology (Oxford) 2009;48:992–6.
WHITTAKER ET AL 316       |
 158. Garrow AP, Silman AJ, Macfarlane GJ. The Cheshire Foot Pain and 
Disability Survey: a population survey assessing prevalence and as-
sociations. Pain 2004;110:378–84.
 159. Waxman R, Woodburn H, Powell M, Woodburn J, Blackburn S, 
Helliwell P. FOOTSTEP: a randomized controlled trial investigating 
the clinical and cost effectiveness of a patient self- management 
program for basic foot care in the elderly. J Clin Epidemiol 
2003;56:1092–9.
 160. Muller S, Roddy E. A Rasch analysis of the Manchester Foot Pain 
and Disability Index. J Foot Ankle Res 2009;2:29.
 161. Kaoulla P, Frescos N, Menz HB. Development and validation of a 
Greek language version of the Manchester Foot Pain and Disability 
Index. Health Qual Life Outcomes 2008;6:39.
 162. Ferrari SC, dos Santos FC, Guarnieri AP, Salvador N, Correa AZ, 
Hala AZ, et al. Índice Manchester de incapacidade associada ao pé 
doloroso no idoso: tradução, adaptação cultural e validação para a 
língua portuguesa. Rev Bras Reumatol 2008;48:335–41.
 163. Gijon-Nogueron G, Ndosi M, Luque-Suarez A, Alcacer-Pitarch B, 
Munuera PV, Garrow A, et al. Cross- cultural adaptation and valida-
tion of the Manchester Foot Pain and Disability Index into Spanish. 
Qual Life Res 2014;23:571–9.
 164. Pedersen CK, Danneskiold-Samsøe B, Garrow AP, Wæhrens 
EE, Bliddal H, Christensen R, et al. Development of a Danish 
language version of the Manchester Foot Pain and Disability In-
dex: reproducibility and construct validity testing. Pain Res Treat 
2013;2013:284903.
 165. Van der Zwaard BC, Terwee CB, Roddy E, Terluin B, van der Horst 
HE, Elders PJ. Evaluation of the measurement properties of the 
Manchester Foot Pain and Disability Index. BMC Musculoskelet 
Disord 2014;15:276.
 166. Erh BX, He HG, Carter KF, Cheung PP, Tan DS, Wang W, et al. 
Validation of the Chinese Manchester Foot Pain and Disability Index 
(C- MFPDI) among patients with inflammatory arthritis. J Foot Ankle 
Res 2019;12:6.
 167. Thomson CE, Beggs I, Martin DJ, McMillan D, Edwards RT, Russell 
D, et al. Methylprednisolone injections for the treatment of Morton 
neuroma: a patient- blinded randomized trial. J Bone Joint Surg Am 
2013;95:790–8.
 168. Ruiz Santiago F, Prados Olleta N, Tomás Muñoz P, Guzmán Álva-
rez L, Martínez Martínez A. Short term comparison between blind 
and ultrasound guided injection in Morton neuroma. Eur Radiol 
2019;29:620–7.
 169. Stephenson J, Farndon L, Concannon M. Analysis of a trial assess-
ing the long- term effectiveness of salicylic acid plasters compared 
with scalpel debridement in facilitating corn resolution in patients 
with multiple corns. J Dermatol 2016;43:662–9.
 170. Gijón-Noguerón G, García-Paya I, Morales-Asencio JM, Jimén-
ez-Cebrián A, Ortega-Ávila AB, Cervera-Marín JA. Short- term ef-
fect of scalpel debridement of plantar callosities versus treatment 
with salicylic acid patches: The EMEDESCA randomized controlled 
trial. J Dermatol 2017;44:706–9.
 171. Abd El Salam MS, Abd Elhafz YN. Low- dye taping versus medial 
arch support in managing pain and pain- related disability in patients 
with plantar fasciitis. Foot Ankle Spec 2011;4:86–91.
 172. De Morais Barbosa C, Barros Bértolo M, Marques Neto JF, Bellini 
Coimbra I, Davitt M, de Paiva Magalhães E. The effect of foot or-
thoses on balance, foot pain and disability in elderly women with 
osteoporosis: a randomized clinical trial. Rheumatology (Oxford) 
2013;52:515–22.
 173. Halstead J, Chapman GJ, Gray JC, Grainger AJ, Brown S, 
Wilkins RA, et al. Foot orthoses in the treatment of sympto-
matic midfoot osteoarthritis using clinical and biomechani-
cal outcomes: a randomised feasibility study. Clin Rheumatol 
2016;35:987–96.
 174. Alcacer-Pitarch B, Buch MH, Gray J, Denton CP, Herrick A, 
Navarro-Coy N, et al. Pressure and pain in systemic sclerosis/
scleroderma: an evaluation of a simple intervention (PISCES): 
randomised controlled trial protocol. BMC Musculoskelet Disord 
2012;13:11.
 175. Spink MJ, Menz HB, Fotoohabadi MR, Wee E, Landorf KB, Hill KD, 
et al. Effectiveness of a multifaceted podiatry intervention to prevent 
falls in community dwelling older people with disabling foot pain: 
randomised controlled trial. BMJ 2011;342:d3411.
 176. Menz HB, Auhl M, Ristevski S, Frescos N, Munteanu SE. Effective-
ness of off- the- shelf, extra- depth footwear in reducing foot pain in 
older people: a randomized controlled trial. J Gerontol A Biol Sci 
Med Sci 2015;70:511–7.
 177. Dawson J, Coffey J, Doll H, Lavis G, Cooke P, Herron M, et al. A 
patient- based questionnaire to assess outcomes of foot surgery: 
validation in the context of surgery for hallux valgus. Qual Life Res 
2006;15:1211–22.
 178. Dawson J, Boller I, Doll H, Lavis G, Sharp R, Cooke P, et al. The 
MOXFQ patient- reported questionnaire: assessment of data qual-
ity, reliability and validity in relation to foot and ankle surgery. Foot 
(Edinb) 2011;21:92–102.
 179. Morley D, Jenkinson C, Doll H, Lavis G, Sharp R, Cooke P, et al. 
The Manchester- Oxford Foot Questionnaire (MOXFQ): develop-
ment and validation of a summary index score. Bone Joint Res 
2013;2:66–9.
 180. Ruiz-Munoz M, Gonzalez-Sanchez M, Li GZ, Cuesta-Vargas AI. 
Manchester- Oxford Foot Questionnaire Chinese version (MOXFQ- 
Ch): a validity and cross- cultural adaptation. Disabil Rehabil 2019. 
E-pub ahead of print.
 181. Venkatesan S, Schotanus MG, Hendrickx RP. Dutch translation of 
the Manchester- Oxford Foot Questionnaire: reassessment of relia-
bility and validity. J Foot Ankle Surg 2016;55:1199–201.
 182. Arbab D, Kuhlmann K, Ringendahl H, Bouillon B, Eysel P, Konig D. 
Reliability, validity and responsiveness of the German Manchester- 
Oxford Foot Questionnaire (MOXFQ) in patients with foot or ankle 
surgery. Foot Ankle Surg 2018;24:481–5.
 183. Marinozzi A, Martinelli N, Panasci M, Cancilleri F, Franceschetti E, 
Vincenzi B, et al. Italian translation of the Manchester- Oxford Foot 
Questionnaire, with re- assessment of reliability and validity. Qual 
Life Res 2009;18:923–7.
 184. Park MJ, Ko YC, Huh JW, Park SH, Park TH, Park JH. Vali-
dation of the Korean version of the Manchester- Oxford Foot 
Questionnaire in patients with hallux valgus. J Foot Ankle Surg 
2017;56:252–4.
 185. Mousavian A, Ebrahimzadeh MH, Birjandinejad A, Omidi-Kashani F, 
Kachooei AR. Translation and cultural adaptation of the Manchester- 
Oxford Foot Questionnaire (MOXFQ) into Persian language. Foot 
(Edinb) 2015;25:224–7.
 186. Garces JB, Winson I, Goldhahn S, Castro MD, Swords MP, Gru-
jic L, et al. Reliability, validity and responsiveness of the Spanish 
Manchester- Oxford Foot Questionnaire (MOXFQ) in patients with 
foot or ankle surgery. Foot Ankle Surg 2016;22:59–70.
 187. Talu B, Bayramlar K, Bek N, Yakut Y. Validity and reliability of the 
Turkish version of the Manchester- Oxford Foot Questionnaire for 
hallux valgus deformity evaluation. Acta Orthop Traumatol Turc 
2016;50:207–13.
 188. Arbab D, Kuhlmann K, Schnurr C, Lüring C, König D, Bouillon 
B. Comparison of the Manchester- Oxford Foot Questionnaire 
(MOXFQ) and the Self- Reported Foot and Ankle Outcome Score 
(SEFAS) in patients with foot or ankle surgery. Foot Ankle Surg 
2019;25:361–5.
 189. Maher AJ, Kilmartin TE. An analysis of Euroqol EQ- 5D and Man-
chester Oxford Foot Questionnaire scores six months following po-
diatric surgery. J Foot Ankle Res 2012;5:17.
MEASURES OF FOOT PAIN, FUNCTION, AND GENERAL HEALTH |      317
 190. Dawson J, Boller I, Doll H, Lavis G, Sharp R, Cooke P, et al. Respon-
siveness of the Manchester- Oxford Foot Questionnaire (MOXFQ) 
compared with AOFAS, SF- 36 and EQ- 5D assessments following 
foot or ankle surgery. J Bone Joint Surg Br 2012;94:215–21.
 191. Dawson J, Boller I, Doll H, Lavis G, Sharp R, Cooke P, et al. Mini-
mally important change was estimated for the Manchester- Oxford 
Foot Questionnaire after foot/ankle surgery. J Clin Epidemiol 
2014;67:697–705.
 192. Mahadevan D, Attwal M, Bhatt R, Bhatia M. Corticosteroid injection 
for Morton’s neuroma with or without ultrasound guidance: a ran-
domised controlled trial. Bone Joint J 2016;98-B:498–503.
 193. Lee DO, Yoo JH, Cho HI, Cho S, Cho HR. Comparing effectiveness 
of polydeoxyribonucleotide injection and corticosteroid injection in 
plantar fasciitis treatment: a prospective randomized clinical study. 
Foot Ankle Surg 2019. E-pub ahead of print.
 194. Kim JK, Chung JY. Effectiveness of polydeoxyribonucleotide in-
jection versus normal saline injection for treatment of chronic 
plantar fasciitis: a prospective randomised clinical trial. Int Orthop 
2015;39:1329–34.
 195. Kearney RS, McKeown R, Gallacher D, Brown J, Mistry D, Parsons 
N, et al. Ankle injury rehabilitation (AIR): a feasibility randomised con-
trolled trial comparing functional bracing to plaster cast in the treat-
ment of adult ankle fractures. Pilot Feasibility Stud 2019;5:55.
 196. Goldberg AJ, Zaidi R, Thomson C, Dore CJ, Skene SS, Cro S, et al. 
Total ankle replacement versus arthrodesis (TARVA): protocol for a 
multicentre randomised controlled trial. BMJ Open 2016;6:e012716.
 197. Maher AJ, Kilmartin TE. Patient- reported outcomes: a new direc-
tion for podiatric surgery. Podiatry Now 2010;13:36–8.
 198. Coster M, Karlsson MK, Nilsson JA, Carlsson A. Validity, reliability, 
and responsiveness of a Self- Reported Foot and Ankle Score (SE-
FAS). Acta Orthop 2012;83:197–203.
 199. Hosman AH, Mason RB, Hobbs T, Rothwell AG. A New Zealand 
national joint registry review of 202 total ankle replacements fol-
lowed for up to 6 years. Acta Orthop 2007;78:584–91.
 200. Dawson J, Fitzpatrick R, Carr A, Murray D. Questionnaire on the 
perceptions of patients about total hip replacement. J Bone Joint 
Surg Br 1996;78:185–90.
 201. Cöster MC, Rosengren BE, Karlsson MK, Carlsson Å. Age- and 
gender- specific normative values for the Self- Reported Foot and 
Ankle Score (SEFAS). Foot Ankle Int 2018;39:1328–34.
 202. Arbab D, Kuhlmann K, Schnurr C, Bouillon B, Luring C, Konig D. 
Reliability, validity and responsiveness of the German Self- Reported 
Foot and Ankle Score (SEFAS) in patients with foot or ankle surgery. 
BMC Musculoskelet Disord 2017;18:409.
 203. Garratt AM, Naumann MG, Sigurdsen U, Utvag SE, Stavem K. 
Evaluation of three patient reported outcome measures following 
operative fixation of closed ankle fractures. BMC Musculoskelet 
Disord 2018;19:134.
 204. Coster MC, Bremander A, Rosengren BE, Magnusson H, Carlsson 
A, Karlsson MK. Validity, reliability, and responsiveness of the Self- 
Reported Foot and Ankle Score (SEFAS) in forefoot, hindfoot, and 
ankle disorders. Acta Orthop 2014;85:187–94.
 205. Coster MC, Nilsdotter A, Brudin L, Bremander A. Minimally impor-
tant change, measurement error, and responsiveness for the Self- 
Reported Foot and Ankle Score. Acta Orthop 2017;88:300–4.
 206. Nilsdotter AK, Coster ME, Bremander A, Coster MC. Patient- 
reported outcome after hallux valgus surgery: a two year follow up. 
Foot Ankle Surg 2019;25:478–81.
 207. Coster MC, Rosengren BE, Bremander A, Karlsson MK. Surgery 
for adult acquired flatfoot due to posterior tibial tendon dysfunction 
reduces pain, improves function and health related quality of life. 
Foot Ankle Surg 2015;21:286–9.
 208. Kamrad I, Carlsson A, Henricson A, Magnusson H, Karlsson MK, 
Rosengren BE. Good outcome scores and high satisfaction rate 
after primary total ankle replacement. Acta Orthop 2017;88:675–
80.
 209. Naumann MG, Sigurdsen U, Utvag SE, Stavem K. Functional out-
comes following surgical- site infections after operative fixation of 
closed ankle fractures. Foot Ankle Surg 2017;23:311–6.
 210. Naumann MG, Sigurdsen U, Utvag SE, Stavem K. Associations of 
timing of surgery with postoperative length of stay, complications, 
and functional outcomes 3- 6 years after operative fixation of closed 
ankle fractures. Injury 2017;48:1662–9.
 211. Henricson A, Fredriksson M, Carlsson A. Total ankle replacement 
and contralateral ankle arthrodesis in 16 patients from the Swedish 
Ankle Registry: self- reported function and satisfaction. Foot Ankle 
Surg 2016;22:32–4.
 212. Protheroe D, Gadgil A. Guided intra- articular corticosteroid injec-
tions in the midfoot. Foot Ankle Int 2018;39:1001–4.
 213. Richter M, Zech S, Geerling J, Frink M, Knobloch K, Krettek C. 
A new foot and ankle outcome score: questionnaire based, sub-
jective, visual- analogue- scale, validated and computerized. Foot 
Ankle Surg 2006;12:191–9.
 214. Stüber J, Zech S, Bay R, Qazzaz A, Richter M. Normative data of 
the Visual Analogue Scale Foot and Ankle (VAS FA) for pathological 
conditions. Foot Ankle Surg 2011;17:166–72.
 215. Angthong C, Chernchujit B, Suntharapa T, Harnroongroj T. Visual 
Analogue Scale Foot and Ankle: validity and reliability of Thai ver-
sion of the new outcome score in subjective form. J Med Assoc 
Thai 2011;94:952–7.
 216. Repo JP, Tukiainen EJ, Roine RP, Kautiainen H, Lindahl J, Ilves 
O, et al. Reliability and validity of the Finnish version of the Visual 
Analogue Scale Foot and Ankle (VAS- FA). Foot Ankle Surg 
2018;24:474–80.
 217. Nair AV, Shamsuddin K, John PS, Hamalainen JA, Kurien MA. 
Correlation of Visual Analogue Scale Foot and Ankle (VAS- FA) to 
AOFAS score in malleolar fractures using Indian language ques-
tionnare. Foot Ankle Surg 2015;21:125–31.
 218. Gur G, Turgut E, Dilek B, Baltaci G, Bek N, Yakut Y. Validity and 
reliability of Visual Analog Scale Foot and Ankle: the Turkish version. 
J Foot Ankle Surg 2017;56:1213–7.
 219. Ponkilainen VT, Tukiainen EJ, Uimonen MM, Hakkinen AH, Repo 
JP. Assessment of the structural validity of three foot and ankle 
specific patient- reported outcome measures. Foot Ankle Surg 
2020;26:169–74.
 220. Ponkilainen VT, Hakkinen AH, Uimonen MM, Tukiainen E, Sande-
lin H, Repo JP. Validation of the Western Ontario and McMaster 
Universities Osteoarthritis Index in patients having undergone ankle 
fracture surgery. J Foot Ankle Surg 2019;58:1100–7.
 221. Jansen H, Jordan M, Frey S, Holscher-Doht S, Meffert R, Heintel 
T. Active controlled motion in early rehabilitation improves outcome 
after ankle fractures: a randomized controlled trial. Clin Rehabil 
2018;32:312–8.
 222. Georgiannos D, Bisbinas I. Endoscopic versus open excision of 
os trigonum for the treatment of posterior ankle impingement syn-
drome in an athletic population: a randomized controlled study with 
5- year follow- up. Am J Sports Med 2017;45:1388–94.
 223. Richter M, Zech S. Leonard J. Goldner Award 2009: intraoperative 
pedobarography leads to improved outcome scores: a level I study. 
Foot Ankle Int 2009;30:1029–36.
 224. Pinitkwamdee S, Laohajaroensombat S, Orapin J, Woratanarat 
P. Effectiveness of extracorporeal shockwave therapy in the treat-
ment of chronic insertional Achilles tendinopathy. Foot Ankle Int 
2020;41:403–10.
WHITTAKER ET AL 318       |
Ta
b
le
 1
. 
P
ra
ct
ic
al
 a
pp
lic
at
io
n*
M
ea
su
re
N
o.
 o
f I
te
m
s
Co
nt
en
t/
D
om
ai
ns
M
et
ho
d 
of
 
Ad
m
in
is
tr
at
io
n
Re
ca
ll 
Pe
rio
d
Re
sp
on
se
 
Fo
rm
at
Ra
ng
e 
of
 
Sc
or
es
Sc
or
e 
In
te
rp
re
ta
tio
n
Av
ai
la
bi
lit
y 
of
 
N
or
m
at
iv
e 
D
at
a
Cr
os
s-
 Cu
ltu
ra
l 
Va
lid
at
io
n
AO
FA
S
AO
FA
S-
 AH
 =
 9
,  
AO
FA
S-
 M
 =
 7
,  
AO
FA
S-
 H
J =
 8
,  
AO
FA
S-
 LJ
 =
 8
Pa
in
 (1
 it
em
), 
fu
nc
tio
n 
(5
- 7
 
ite
m
s)
, a
nd
 
al
ig
nm
en
t (
1 
ite
m
)
Pa
tie
nt
 a
nd
 
cl
in
ic
ia
n 
ad
m
in
is
te
re
d,
 
pa
pe
r a
nd
 p
en
ci
l
U
ns
pe
ci
fie
d
Va
ry
in
g 
Li
ke
rt
 
sc
al
es
0-
 10
0
H
ig
he
r s
co
re
s 
re
pr
es
en
t b
et
te
r 
fo
ot
 h
ea
lth
Ye
s
Ye
s:
 D
ut
ch
, 
G
er
m
an
, I
ta
lia
n,
 
Pe
rs
ia
n,
 
Po
rt
ug
ue
se
, 
an
d 
Tu
rk
is
h
FA
AM
29
Ac
tiv
iti
es
 o
f d
ai
ly
 
liv
in
g 
(2
1 
ite
m
s)
 
an
d 
sp
or
ts
 (6
 
ite
m
s)
Se
lf-
 ad
m
in
is
te
re
d,
 
pa
pe
r a
nd
 p
en
ci
l
1 
w
k
5-
 po
in
t L
ik
er
t 
sc
al
es
0-
 10
0
H
ig
he
r s
co
re
s 
re
pr
es
en
t b
et
te
r 
fo
ot
 h
ea
lth
Ye
s
Ye
s:
 B
ra
zi
lia
n 
Po
rt
ug
ue
se
, 
Ch
in
es
e,
 D
ut
ch
, 
Fr
en
ch
, 
G
er
m
an
, I
ta
lia
n,
 
Ja
pa
ne
se
, 
Pe
rs
ia
n,
 
Sp
an
is
h,
 a
nd
 
Tu
rk
is
h
FA
O
S
42
Pa
in
 (9
 it
em
s)
, o
th
er
 
sy
m
pt
om
s 
(7
 
ite
m
s)
, a
ct
iv
iti
es
 o
f 
da
ily
 li
vi
ng
 (1
7 
ite
m
s)
, s
po
rt
 a
nd
 
re
cr
ea
tio
na
l 
ac
tiv
iti
es
 (5
 it
em
s)
, 
an
d 
fo
ot
-  a
nd
 
an
kl
e-
 re
la
te
d 
qu
al
ity
 o
f l
ife
 (4
 
ite
m
s)
Se
lf-
 ad
m
in
is
te
re
d,
 
pa
pe
r a
nd
 p
en
ci
l 
or
 ta
bl
et
1 
w
k
5-
 po
in
t L
ik
er
t 
sc
al
es
0-
 10
0
H
ig
he
r s
co
re
s 
re
pr
es
en
t w
or
se
 
fo
ot
 h
ea
lth
N
o
Ye
s:
 C
hi
ne
se
, 
D
an
is
h,
 D
ut
ch
, 
G
er
m
an
, 
Ko
re
an
, P
er
si
an
, 
Th
ai
, a
nd
 
Tu
rk
is
h
FF
I- R
Lo
ng
 fo
rm
 =
 
68
, s
ho
rt
 
fo
rm
 =
 3
4
Pa
in
 a
nd
 s
tif
fn
es
s 
(2
0 
ite
m
s)
, 
di
ff
ic
ul
ty
 (2
0 
ite
m
s)
, a
ct
iv
ity
 
lim
ita
tio
n 
(9
 
ite
m
s)
, a
nd
 s
oc
ia
l/
em
ot
io
na
l i
ss
ue
s 
(1
9 
ite
m
s)
Se
lf-
 ad
m
in
is
te
re
d,
 
pa
pe
r a
nd
 p
en
ci
l
1 
w
k
4-
 po
in
t L
ik
er
t 
sc
al
es
0-
 10
0
H
ig
he
r s
co
re
s 
re
pr
es
en
t w
or
se
 
fo
ot
 h
ea
lth
N
o
Ye
s:
 B
ra
zi
lia
n 
Po
rt
ug
ue
se
, 
Po
lis
h,
 a
nd
 
Tu
rk
is
h
FH
SQ
13
Fo
ot
 p
ai
n 
(4
 
qu
es
tio
ns
), 
fo
ot
 
fu
nc
tio
n 
(4
 
qu
es
tio
ns
), 
fo
ot
w
ea
r (
3 
qu
es
tio
ns
), 
an
d 
ge
ne
ra
l f
oo
t 
he
al
th
 (2
 
qu
es
tio
ns
)
Se
lf-
 ad
m
in
is
te
re
d,
 
pa
pe
r a
nd
 p
en
ci
l
1 
w
k
5-
 po
in
t L
ik
er
t 
sc
al
es
0-
 10
0
H
ig
he
r s
co
re
s 
re
pr
es
en
t b
et
te
r 
fo
ot
 h
ea
lth
N
o
Ye
s:
 B
ra
zi
lia
n 
Po
rt
ug
ue
se
, 
Va
le
nc
ia
n,
 
Sp
an
is
h,
 F
re
nc
h,
 
an
d 
D
an
is
h
 (C
on
tin
ue
d)
MEASURES OF FOOT PAIN, FUNCTION, AND GENERAL HEALTH |      319
M
ea
su
re
N
o.
 o
f I
te
m
s
Co
nt
en
t/
D
om
ai
ns
M
et
ho
d 
of
 
Ad
m
in
is
tr
at
io
n
Re
ca
ll 
Pe
rio
d
Re
sp
on
se
 
Fo
rm
at
Ra
ng
e 
of
 
Sc
or
es
Sc
or
e 
In
te
rp
re
ta
tio
n
Av
ai
la
bi
lit
y 
of
 
N
or
m
at
iv
e 
D
at
a
Cr
os
s-
 Cu
ltu
ra
l 
Va
lid
at
io
n
LF
IS
- R
A
51
Im
pa
irm
en
t/
fo
ot
w
ea
r (
21
 
ite
m
s)
 a
nd
 a
ct
iv
ity
 
lim
ita
tio
n/
pa
rt
ic
ip
at
io
n 
re
st
ric
tio
n 
(3
0 
ite
m
s)
Se
lf-
 ad
m
in
is
te
re
d,
 
pa
pe
r a
nd
 p
en
ci
l
At
 th
e 
m
om
en
t
2 
re
sp
on
se
 
op
tio
ns
: 
tr
ue
 a
nd
 
no
t t
ru
e
0-
 51
H
ig
he
r s
co
re
s 
re
pr
es
en
t w
or
se
 
fo
ot
 h
ea
lth
N
o
Ye
s:
 D
ut
ch
, 
H
un
ga
ria
n,
 a
nd
 
G
er
m
an
M
FP
D
I
19
Pa
in
 in
te
ns
ity
 (5
 
ite
m
s)
, f
un
ct
io
na
l 
lim
ita
tio
n 
(1
0 
ite
m
s)
, a
nd
 
pe
rs
on
al
 
ap
pe
ar
an
ce
 (2
 
ite
m
s)
, p
lu
s 
2 
ite
m
s 
ab
ou
t w
or
k 
an
d 
le
is
ur
e 
ac
tiv
iti
es
Se
lf-
 ad
m
in
is
te
re
d,
 
pa
pe
r a
nd
 p
en
ci
l
1 
m
o
3 
re
sp
on
se
 
op
tio
ns
: 
no
ne
 o
f t
he
 
tim
e,
 o
n 
so
m
e 
da
ys
, 
or
 o
n 
m
os
t 
da
ys
/e
ve
ry
 
da
y
0-
 34
 o
r 
17
- 5
1†
H
ig
he
r s
co
re
s 
re
pr
es
en
t w
or
se
 
fo
ot
 h
ea
lth
N
o
Ye
s:
 G
re
ek
, 
Po
rt
ug
ue
se
, 
Sp
an
is
h,
 D
an
is
h,
 
D
ut
ch
, a
nd
 
Ch
in
es
e
M
O
XF
Q
16
W
al
ki
ng
/s
ta
nd
in
g 
pr
ob
le
m
s 
(7
 
ite
m
s)
, p
ai
n 
(5
 
ite
m
s)
, a
nd
 is
su
es
 
re
la
te
d 
to
 s
oc
ia
l 
in
te
ra
ct
io
n 
(4
 
ite
m
s)
; a
n 
ov
er
al
l 
su
m
m
ar
y 
in
de
x 
sc
or
e 
ca
n 
al
so
 b
e 
ca
lc
ul
at
ed
Se
lf-
 ad
m
in
is
te
re
d,
 
pa
pe
r a
nd
 p
en
ci
l
4 
w
k
5-
 po
in
t L
ik
er
t 
sc
al
es
0-
 10
0
H
ig
he
r s
co
re
s 
re
pr
es
en
t w
or
se
 
fo
ot
 h
ea
lth
N
o
Ye
s:
 C
hi
ne
se
, 
D
ut
ch
, G
er
m
an
, 
Ita
lia
n,
 K
or
ea
n,
 
Pe
rs
ia
n,
 
Sp
an
is
h,
 a
nd
 
Tu
rk
is
h
SE
FA
S
12
Pa
in
, f
un
ct
io
n,
 
lim
ita
tio
n 
of
 
fu
nc
tio
n,
 a
nd
 
ot
he
r s
ym
pt
om
s,
 
(th
at
 a
re
 n
ot
 
se
pa
ra
te
d 
in
to
 
do
m
ai
ns
)
Pa
tie
nt
 a
nd
 
cl
in
ic
ia
n 
ad
m
in
is
te
re
d,
 
pa
pe
r a
nd
 p
en
ci
l
U
ns
pe
ci
fie
d
5-
 po
in
t L
ik
er
t 
sc
al
es
0-
 48
H
ig
he
r s
co
re
s 
re
pr
es
en
t l
es
s 
se
ve
re
 p
ai
n 
an
d 
di
sa
bi
lit
y
Ye
s
Ye
s:
 S
w
ed
is
h,
 
G
er
m
an
, a
nd
 
N
or
w
eg
ia
n
VA
S-
 FA
20
Pa
in
, f
un
ct
io
n,
 a
nd
 
ot
he
r c
om
pl
ai
nt
s
Pa
tie
nt
 a
nd
 
cl
in
ic
ia
n 
ad
m
in
is
te
re
d,
 
pa
pe
r a
nd
 p
en
ci
l
U
ns
pe
ci
fie
d
Vi
su
al
 a
na
lo
g 
sc
al
es
To
ta
l s
co
re
 
an
d 
ea
ch
 
do
m
ai
n:
 
0-
 10
0
H
ig
he
r s
co
re
s 
re
pr
es
en
t l
es
s 
se
ve
re
 p
ai
n,
 
di
sa
bi
lit
y, 
an
d 
sy
m
pt
om
s
Ye
s
Ye
s:
 G
er
m
an
, 
Fi
nn
is
h,
 In
di
an
 
(M
al
ay
al
am
), 
Th
ai
, a
nd
 
Tu
rk
is
h
* 
AH
 =
 a
nk
le
/h
in
df
oo
t; 
AO
FA
S 
= 
Am
er
ic
an
 O
rt
ho
pa
ed
ic
 F
oo
t 
an
d 
An
kl
e 
So
ci
et
y;
 F
AA
M
 =
 F
oo
t 
an
d 
An
kl
e 
Ab
ili
ty
 M
ea
su
re
; F
AO
S 
= 
Fo
ot
 a
nd
 A
nk
le
 O
ut
co
m
e 
Sc
or
e;
 F
FI
- R
 =
 F
oo
t 
Fu
nc
tio
n 
In
de
x–
Re
vi
se
d;
 F
H
SQ
 =
 F
oo
t 
H
ea
lth
 S
ta
tu
s 
Q
ue
st
io
nn
ai
re
; 
H
J 
= 
ha
llu
x 
m
et
at
ar
so
ph
al
an
ge
al
- in
te
rp
ha
la
ng
ea
l; 
LF
IS
- R
A 
= 
Le
ed
s 
Fo
ot
 I
m
pa
ct
 S
ca
le
 f
or
 R
he
um
at
oi
d 
Ar
th
rit
is
; 
LJ
 =
 le
ss
er
 
m
et
at
ar
so
ph
al
an
ge
al
- in
te
rp
ha
la
ng
ea
l; 
M
 =
 m
id
fo
ot
; M
FP
D
I =
 M
an
ch
es
te
r F
oo
t P
ai
n 
an
d 
D
is
ab
ili
ty
 In
de
x;
 M
O
XF
Q
 =
 M
an
ch
es
te
r-
 O
xf
or
d 
Fo
ot
 Q
ue
st
io
nn
ai
re
; S
EF
AS
 =
 S
el
f- R
ep
or
te
d 
Fo
ot
 a
nd
 
An
kl
e 
Sc
or
e;
 V
AS
- F
A 
= 
Vi
su
al
 A
na
lo
g 
Sc
al
e–
Fo
ot
 a
nd
 A
nk
le
.
† 
D
ep
en
di
ng
 o
n 
th
e 
m
et
ho
d 
us
ed
 to
 c
al
cu
la
te
 th
e 
sc
or
es
. 
Ta
b
le
 1
. 
 (C
on
t’d
)
WHITTAKER ET AL 320       |
Ta
b
le
 2
. 
P
sy
ch
om
et
ric
s*
M
ea
su
re
Fl
oo
r, 
Ce
ili
ng
 
Ef
fe
ct
s
Re
lia
bi
lit
y†
Va
lid
ity
Re
sp
on
si
ve
ne
ss
‡
M
in
im
al
ly
 
Im
po
rt
an
t 
D
iff
er
en
ce
s
G
en
er
al
iz
ab
ili
ty
U
se
 in
 
RC
Ts
AO
FA
S
Ce
ili
ng
 e
ffe
ct
 
fo
r 
AO
FA
S-
 M
 
an
d 
AO
FA
S-
 LJ
In
te
rn
al
 c
on
si
st
en
cy
: 
un
kn
ow
n;
 te
st
- r
et
es
t: 
un
kn
ow
n
Co
nt
en
t: 
no
; c
rit
er
io
n:
 
no
; c
on
st
ru
ct
: n
o
AO
FA
S-
 AH
: h
ig
h
AO
FA
S-
 AH
: 7
.9
- 3
0.
2
Pr
ed
om
in
an
tly
 
or
th
op
ed
ic
Ex
te
ns
iv
e
FA
AM
Fl
oo
r e
ffe
ct
 
fo
r s
po
rt
s 
su
bs
ca
le
 in
 
ce
rt
ai
n 
po
pu
la
tio
ns
In
te
rn
al
 c
on
si
st
en
cy
: 
ex
ce
lle
nt
; t
es
t- r
et
es
t: 
ex
ce
lle
nt
Co
nt
en
t: 
ye
s;
 
cr
ite
rio
n:
 n
o;
 
co
ns
tr
uc
t: 
ye
s
Ac
tiv
iti
es
 o
f d
ai
ly
 li
vi
ng
: 
ve
ry
 h
ig
h;
 s
po
rt
s:
 v
er
y 
hi
gh
Ac
tiv
iti
es
 o
f d
ai
ly
 
liv
in
g:
 3
- 2
5;
 
sp
or
ts
: 9
- 7
7
Br
oa
d
Ex
te
ns
iv
e
FA
O
S
Ce
ili
ng
 e
ffe
ct
s
In
te
rn
al
 c
on
si
st
en
cy
: f
ai
r t
o 
ex
ce
lle
nt
; t
es
t- r
et
es
t: 
go
od
 
to
 e
xc
el
le
nt
Co
nt
en
t: 
ye
s;
 
cr
ite
rio
n:
 n
o;
 
co
ns
tr
uc
t: 
ye
s
Pa
in
: m
od
er
at
e 
to
 h
ig
h;
 
ot
he
r s
ym
pt
om
s:
 lo
w
 to
 
hi
gh
; a
ct
iv
iti
es
 o
f d
ai
ly
 
liv
in
g:
 lo
w
 to
 h
ig
h;
 s
po
rt
 
an
d 
re
cr
ea
tio
n:
 lo
w
 to
 
hi
gh
; q
ua
lit
y 
of
 li
fe
: 
m
od
er
at
e 
to
 h
ig
h
Pa
in
: 7
- 1
3;
 o
th
er
 
sy
m
pt
om
s:
 1
3-
 15
; 
ac
tiv
iti
es
 o
f d
ai
ly
 
liv
in
g:
 1
4-
 18
; s
po
rt
 
an
d 
re
cr
ea
tio
n:
 
23
- 3
3;
 q
ua
lit
y 
of
 
lif
e:
 2
2
Pr
ed
om
in
an
tly
 s
ur
gi
ca
l
Li
m
ite
d
FF
I- R
N
o
In
te
rn
al
 c
on
si
st
en
cy
: 
ex
ce
lle
nt
; t
es
t- r
et
es
t: 
un
kn
ow
n
Co
nt
en
t: 
ye
s;
 
cr
ite
rio
n:
 n
o;
 
co
ns
tr
uc
t: 
ye
s
Pa
in
: v
er
y 
hi
gh
; s
tif
fn
es
s:
 
m
ed
iu
m
 to
 h
ig
h;
 
di
ff
ic
ul
ty
: m
ed
iu
m
 to
 
hi
gh
 (F
FI
- R
 s
ho
rt
 fo
rm
)
U
nk
no
w
n
Br
oa
d
Li
m
ite
d
FH
SQ
U
nc
er
ta
in
In
te
rn
al
 c
on
si
st
en
cy
: 
ex
ce
lle
nt
; t
es
t- r
et
es
t: 
go
od
 
to
 e
xc
el
le
nt
Co
nt
en
t: 
ye
s;
 
cr
ite
rio
n:
 n
o;
 
co
ns
tr
uc
t: 
ye
s
Pa
in
: v
er
y 
hi
gh
; f
un
ct
io
n:
 
ve
ry
 h
ig
h;
 fo
ot
w
ea
r: 
lo
w
; 
ge
ne
ra
l f
oo
t h
ea
lth
: 
m
od
er
at
e
Pa
in
: 1
1-
 13
; 
fu
nc
tio
n:
 7
- 1
0;
 
fo
ot
w
ea
r: 
1-
 2;
 
ge
ne
ra
l f
oo
t 
he
al
th
: 0
- 1
0
Br
oa
d
Ex
te
ns
iv
e
LF
IS
- R
A
N
o
In
te
rn
al
 c
on
si
st
en
cy
: 
un
kn
ow
n;
 te
st
- r
et
es
t: 
go
od
 to
 e
xc
el
le
nt
Co
nt
en
t: 
ye
s;
 
cr
ite
rio
n:
 n
o;
 
co
ns
tr
uc
t: 
ye
s
M
od
er
at
e
U
nk
no
w
n
Rh
eu
m
at
oi
d 
ar
th
rit
is
Li
m
ite
d
M
FP
D
I
N
o
In
te
rn
al
 c
on
si
st
en
cy
: g
oo
d 
to
 e
xc
el
le
nt
; t
es
t- r
et
es
t: 
po
or
 to
 g
oo
d
Co
nt
en
t: 
ye
s;
 
cr
ite
rio
n:
 y
es
; 
co
ns
tr
uc
t: 
ye
s
Pa
in
 in
te
ns
ity
: s
m
al
l; 
fu
nc
tio
na
l l
im
ita
tio
n:
 
sm
al
l; 
pe
rs
on
al
 
ap
pe
ar
an
ce
: n
eg
lig
ib
le
U
nk
no
w
n
Br
oa
d
Li
m
ite
d
M
O
XF
Q
N
o
In
te
rn
al
 c
on
si
st
en
cy
: 
ex
ce
lle
nt
; t
es
t- r
et
es
t: 
ex
ce
lle
nt
Co
nt
en
t: 
ye
s;
 
cr
ite
rio
n:
 n
o;
 
co
ns
tr
uc
t: 
ye
s
W
al
ki
ng
/s
ta
nd
in
g:
 
m
od
er
at
e 
to
 v
er
y 
hi
gh
; 
pa
in
: v
er
y 
hi
gh
; s
oc
ia
l 
in
te
ra
ct
io
n:
 v
er
y 
hi
gh
W
al
ki
ng
/
st
an
di
ng
:1
6;
 p
ai
n:
 
10
- 1
2;
 s
oc
ia
l 
in
te
ra
ct
io
n:
 9
- 2
4
Pr
ed
om
in
an
tly
 s
ur
gi
ca
l
Li
m
ite
d
SE
FA
S
N
o
In
te
rn
al
 c
on
si
st
en
cy
: 
ex
ce
lle
nt
; t
es
t- r
et
es
t: 
ex
ce
lle
nt
Co
nt
en
t: 
ye
s;
 
cr
ite
rio
n:
 n
o;
 
co
ns
tr
uc
t: 
ye
s
Ve
ry
 h
ig
h
To
ta
l s
co
re
: 5
Pr
ed
om
in
an
tly
 s
ur
gi
ca
l
N
on
e
VA
S-
 FA
N
o
In
te
rn
al
 c
on
si
st
en
cy
: 
ex
ce
lle
nt
; t
es
t- r
et
es
t: 
ex
ce
lle
nt
Co
nt
en
t: 
no
; c
rit
er
io
n:
 
no
; c
on
st
ru
ct
: y
es
U
nk
no
w
n
U
nk
no
w
n
Br
oa
d
Li
m
ite
d
* 
AH
 =
 a
nk
le
/h
in
df
oo
t; 
AO
FA
S 
= 
Am
er
ic
an
 O
rt
ho
pa
ed
ic
 F
oo
t a
nd
 A
nk
le
 S
oc
ie
ty
; F
AA
M
 =
 F
oo
t a
nd
 A
nk
le
 A
bi
lit
y 
M
ea
su
re
; F
AO
S 
= 
Fo
ot
 a
nd
 A
nk
le
 O
ut
co
m
e 
Sc
or
e;
 F
FI
- R
 =
 F
oo
t F
un
ct
io
n 
In
de
x–
Re
vi
se
d;
 F
H
SQ
 =
 F
oo
t H
ea
lth
 S
ta
tu
s 
Q
ue
st
io
nn
ai
re
; L
FI
S-
 RA
 =
 L
ee
ds
 F
oo
t I
m
pa
ct
 S
ca
le
 fo
r 
Rh
eu
m
at
oi
d 
Ar
th
rit
is
; L
J =
 le
ss
er
 m
et
at
ar
so
ph
al
an
ge
al
- in
te
rp
ha
la
ng
ea
l; 
M
 =
 m
id
fo
ot
; M
FP
D
I =
 
M
an
ch
es
te
r 
Fo
ot
 P
ai
n 
an
d 
D
is
ab
ili
ty
 In
de
x;
 M
O
XF
Q
 =
 M
an
ch
es
te
r-
 O
xf
or
d 
Fo
ot
 Q
ue
st
io
nn
ai
re
; R
CT
 =
 r
an
do
m
 c
on
tr
ol
le
d 
tr
ia
l; 
SE
FA
S 
= 
Se
lf-
 Re
po
rt
ed
 F
oo
t a
nd
 A
nk
le
 S
co
re
; V
AS
- F
A 
= 
Vi
su
al
 
An
al
og
 S
ca
le
–F
oo
t a
nd
 A
nk
le
.
† 
D
es
cr
ip
to
rs
 b
as
ed
 o
n 
th
e 
fo
llo
w
in
g 
sc
al
e,
 ir
re
sp
ec
tiv
e 
of
 re
lia
bi
lit
y 
st
at
is
tic
s 
us
ed
: p
oo
r (
<0
.4
0)
, f
ai
r (
0.
40
- 0
.5
9)
, g
oo
d 
(0
.6
0-
 0.
74
), 
an
d 
ex
ce
lle
nt
 (0
.7
5-
 1.
00
). 
‡ 
D
es
cr
ip
to
rs
 b
as
ed
 o
n 
an
 a
gg
re
ga
te
 o
f t
he
 re
sp
on
si
ve
ne
ss
 s
ta
tis
tic
s 
re
po
rt
ed
 fo
r e
ac
h 
m
ea
su
re
. 
